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Abstract
Tissue engineering describes the combination of cells and biomaterials for the successful
reconstruction of biological tissues. Naturally, a wide selection of biomaterials exists depending on the tissue of interest. Collagen is an abundant structural protein in the human
body and is therefore a regular choice when fabricating biotissue analogues. As such, the
tunability of mechanical and biological properties becomes very important when replicating the biological environment in vitro.
Different methods for forming three-dimensional (3D) networks in biopolymers exist depending on the required mechanical and biological properties. One technique, electrocompaction, was reported to produce constructs with highly aligned collagen ﬁbres, yielding much denser and stiffer scaffolds when compared to gelled collagen.

In this research, we have shown how the underlying principle of electrocompaction was
adapted to form curved and tubular collagen scaffolds.
First, we describe a parametric design approach to generate a compaction platform based
on the desired geometry of the ﬁnal collagen construct. Using rapid prototyping techniques, this platform was fabricated within hours which greatly reduces the time for the
fabrication of patient- or deﬁcient-speciﬁc constructs and may pave the way for this method
to enter the clinic. The compacted collagen constructs showed a compaction degree of
45% and light transmission of around 90% within the visible spectrum.
Second, and most novel, the electrochemical compaction of tubular collagen constructs
is reported. Here, we highlight their potential application as nerve conduits. PC12 cells
demonstrated the formation and branching of neurites and aggregated to clusters upon
induction of their neural phenotype using neural growth factor (NGF). Patches and lenses
have shown great cytocompatibility with human cornea epithelial cells, suggesting the
suitability of the constructs as cell-delivery vehicles.
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The results suggest that the material and the technique are suitable to produce medical
devices that support the proliferation and differentiation of neural and epithelial cells suggesting their suitability as corneal shields and nerve conduits.
With tubes being a recurring shape throughout the human body, this method may provide
a new way of forming tissue guides for a range of other applications, such as liver bile
ducts, muscular tendons or even angiogenic conduits. Lastly, when forming 3D networks,
crosslinking collagen with electrochemical compaction may pose a viable alternative to
methacrylating biopolymers.

Acknowledgments
I would like to thank my main supervisor professor Gordon G. Wallace and my co-supervisors
Dr. Zhilian Yue and Dr. Xiao Liu for the opportunity to work at IPRI for the time of my
project. Thank you for providing guidance and constructive suggestions when needed.

v

Contents
Abstract

iii

List of Figures

ix

Abbreviations

xi

Layman’s summary

1

1

Introduction

3

1.1

Collagen as a biopolymer . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3

1.1.1

Structural composition . . . . . . . . . . . . . . . . . . . . . . . . . .

3

1.1.2

In vitro ﬁbrillogenesis and electrochemical compaction . . . . . . . .

4

Collagen as a biomedical product . . . . . . . . . . . . . . . . . . . . . . . .

6

1.2.1

Commercially available products . . . . . . . . . . . . . . . . . . . .

7

1.2.2

Safety concerns . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

8

Aims of this research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

8

1.2

1.3

Statement of Signiﬁcance

10

2 Material & Methods

11

2.1

Material preparation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.1.1

Bovine Collagen Type I solution . . . . . . . . . . . . . . . . . . . . . 11

2.1.2

Riboﬂavin / 10x PBS solution for crosslinking . . . . . . . . . . . . . 11

2.2 Electrode and chamber fabrication . . . . . . . . . . . . . . . . . . . . . . . 12
2.2.1

Electrode fabrication for EC chambers . . . . . . . . . . . . . . . . . 12

2.2.2 Chamber fabrication . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.2.3 Assembly of the EC device . . . . . . . . . . . . . . . . . . . . . . . . 12
2.3 Fabrication of EC collagen constructs . . . . . . . . . . . . . . . . . . . . . . 13
vi

vii

CONTENTS
2.3.1

Electrochemical compaction of collagen . . . . . . . . . . . . . . . . 13

2.3.2 Post processing EC collagen structures . . . . . . . . . . . . . . . . . 13
2.4 Characterization of EC collagen . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.4.1

Rheological characterization . . . . . . . . . . . . . . . . . . . . . . . 14

2.4.2 Transmission of UV-Vis light through EC constructs . . . . . . . . . . 14
2.4.3 Water content of EC samples . . . . . . . . . . . . . . . . . . . . . . 14
2.4.4 Degradation of EC collagen over time . . . . . . . . . . . . . . . . . . 14
2.4.5 Morphology and ﬁbre alignment of EC collagen constructs . . . . . . 15
2.5 Cell lines and culture conditions . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.5.1

Human cornea epithelial cells (hCECs) . . . . . . . . . . . . . . . . . 15

2.5.2 PC12 cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.5.3 Seeding EC collagen constructs . . . . . . . . . . . . . . . . . . . . . 16
2.6 Histological analyses of EC collagen constructs . . . . . . . . . . . . . . . . 16
3 Results & Discussion
3.1

18

Electrocompaction to ﬂat patches and curved lenses . . . . . . . . . . . . . 18
3.1.1

Chamber design and development . . . . . . . . . . . . . . . . . . . 18

3.1.2

Fabrication of EC patches and lenses . . . . . . . . . . . . . . . . . . 18

3.2 Electrocompaction of tubes . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
3.2.1

Chamber design and fabrication . . . . . . . . . . . . . . . . . . . . . 21

3.2.2 Fabrication of the collagen tube . . . . . . . . . . . . . . . . . . . . . 23
3.3 Characterization of EC constructs . . . . . . . . . . . . . . . . . . . . . . . . 25
3.3.1

Light transmission through EC constructs . . . . . . . . . . . . . . . 25

3.3.2 Degree of compaction, water content and passive degradation of
EC constructs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.3.3 Rheological characterisation of EC constructs . . . . . . . . . . . . . 28
3.3.4 Morphology and ﬁbre alignment of EC constructs . . . . . . . . . . . 29
3.4 Using EC collagen constructs as a medical device . . . . . . . . . . . . . . . 30
3.4.1

Flat patches and curved lenses . . . . . . . . . . . . . . . . . . . . . 30

3.4.2 Collagen tubes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
4 Conclusion & Future Outlook

35

CONTENTS

viii

Bibliography

37

A Appendix

43

A.1 3D Disk EC chamber . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
A.2 3D Lens EC chamber . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
A.3 3D Tube EC chamber . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46

List of Figures
3.1

EC chamber forming ﬂat and curved collagen constructs. (A) Concept of
two electrodes forming a lens (B) Assembly of lens compaction chamber
and (C) its electrodes. (D) Flat compaction chamber and (E) its electrodes.

19

3.2 (A) Screenshot of the parameters used to design the lens in SolidWorks.
(B) Technical drawing of the resulting lens. . . . . . . . . . . . . . . . . . . . 19
3.3 Flat collagen patches (A) top view (B) side view . . . . . . . . . . . . . . . . 20
3.4 Current drawn over time when EC collagen at different voltages . . . . . . . 20
3.5 Preliminary experiment showing the feasibility of tubular EC (A) Two needles held in place concentrically served as electrodes forming a tubular
caveat for the collagen to compact in (B) close-up of the EC collagen tube . 22
3.6 Tubular compaction chamber: (A) colour coded render: green: outer chamber (one part), gold: inner needle (short version), black: rubber septum,
copper: outer electrode (B) colour coded render of cross-section (C) 3Dprinted chamber (open) holding the central needle and outer electrode (D)
chamber when closed (E) EC collagen extruding onto needle (old model
with short needle) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.7 EC collagen tube (A) overview (B) tubular opening (C) cross-section to measure the diameter and thickness . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.8 Light transmission of EC collagen patches in the visible spectrum . . . . . . 26
3.9 Passive degradation of EC collagen in DMEM over 14 days . . . . . . . . . . 28
3.10 Storage (G’) and Loss Modulus (G”) of EC collagen after crosslinking between 0 and 10 % strain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29

ix

LIST OF FIGURES

x

3.11 Morphology of EC collagen constructs (A) cross-section of disk-shaped
patches immediately after compaction (B) hollow tube after cross-linking
and soaking in PBS for 24 h (C) SEM of disk patches (D) SEM of tubular
construct (debris stems from storage) . . . . . . . . . . . . . . . . . . . . . 30
3.12 Live (green) / Dead (red) staining of human epithelial cells (A) Curved lensshaped construct after 3 days of culture (B) Flat disk patches after prolonged culture of 17 days. (N = 1) . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.13 PC12 cells on EC collagen tubes subjected to NGF (A) Neurite branching
slowly visible after 24 hours (B) After 7 days, branching clearly visible and
cells appear to form clusters (C-F) beta-III-tubulin staining (red) and DAPI
(blue) after 10 days. Clear formation of clusters and strong branching visible between clusters. (N = 1) . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
A.1 3D model of the disk compaction chamber . . . . . . . . . . . . . . . . . . . 44
A.2 3D model of the lens compaction chamber . . . . . . . . . . . . . . . . . . . 45
A.3 3D model of the tubular compaction chamber . . . . . . . . . . . . . . . . . 46

LIST OF FIGURES

Abbreviations
3D Three-Dimensional
CAD Computer Aided Design
cm centimeter
DC Direct Current
DMEK Descemet Membrane Endothelial Keratoplasty
DMEM Dulbecco’s Modiﬁed Eagle’s Medium
DMSO Dimethyl sulfoxide
DSEK Descemet’s Stripping Endothelial Keratoplasty
E Electric Field Strength
EC Electrochemical Compaction
ECM Extra-cellular marix
EDC–NHS 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide– N-hydroxysuccinimide
FBS Fetal bovine serum
FDA Food and Drug Administration
G’ Storage Modulus
G” Loss Modulus
GMP Good Manufacturing Practice
hCECs Human cornea epithelial cells
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HMDS Hexamethyldisilazane
Hz Hertz
IgE Immunoglobulin E

xi

LIST OF FIGURES
kPa Kilopascal
kV Kilovolt
µA Microampere
mg milligram
ml millilitre
mM millimolar
MPa Megapascal
NGF Neural Growth Factor
nm nanometer
PBS Phosphate-buffered saline
PEG Polyethylene Glycol
RGD Arginylglycylaspartic acid
RT Room Temperature
SEM Scanning electron microscopy
SLA Stereolithography
STL Standard Triangle Language
µL Microlitre
µm micrometer
V Volts

xii

Layman’s summary
Collagen is the most common protein in human tissues providing great structural integrity
and a favourable environment for cellular attachment. As such, it becomes a promising
material in the ﬁeld of tissue engineering and regenerative medicine. Its ability to assemble into ﬁbrillar structures opens the possibility to mimic a range of biological tissues in
vitro.
In previous results, collagen is mostly gelled to form a favourable environment for cell
culture. However, this method yields gels with a very low stiffness and processability.
In this research, we adapted a novel method, to form constructs of higher strength. Electrochemical compaction (EC) allows the formation of very dense collagen constructs
when aligning the molecules to form a sheet. So far, this method has been shown to
form collagen threads, patches and lenses.

In this study, we report two things. On the one hand, we want to show a more automated
process of designing compaction chambers. Using a parametric design, the 3D model is
generated based on the required dimensions of the collagen constructs. These chambers can be fabricated using rapid prototyping techniques. Consequently, this approach
allows the user to change the design fast and produce the required chamber within hours,
potentially accelerating the use of such constructs in the clinic.
On the other hand, we want to report the EC of collagen into a tube. This shape has previously not been achieved with this method. However, as tubes are a recurring shape within
the human body, the creation of these constructs will hopefully prove useful.

We have demonstrated a high viability of human cornea epithelial cells on ﬂat and
curved EC constructs. This shows that these constructs may serve as cell-delivery vehicles within the eyes or as collagen lenses shielding the cornea from the impact of the
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eyelid after surgery. Moreover, we have demonstrated that PC12 cells have shown a characteristic phenotype and behaviour similar to neural cells, suggesting a high feasibility of
our tubes as nerve conduits.

In summary, we have advanced a novel approach of forming collagen constructs. We
reported an easy way of generating EC chambers that can fabricate collagen constructs
with speciﬁc dimensions. Moreover, we have shown the fabrication of continuous tubes
which may serve in a broad range of applications in tissue engineering. The fabricated
constructs demonstrated high viability of cells and have shown to provide a favourable
environment.

Chapter 1

Introduction
1.1

Collagen as a biopolymer

Collagen is the most abundant protein in the human extra-cellular matrix (ECM) [1] and the
major protein of ligaments, tendons and the cornea [2], making it an interesting candidate
for the ﬁeld of tissue engineering. With up to 90%, collagen type I, II and III are the most
prevalent types. The molecule’s base structure consists of a triple helix that is roughly 300
nm long and 1.5 nm thick. In vivo, collagen molecules assemble into triple-stranded ﬁbrils
which in turn may assemble into larger structures to enhance the mechanical stability of
the protein [3].

1.1.1

Structural composition

Collagens form different types of three-dimensional (3D) networks to match the mechanical requirements of tissues in vivo. For example, collagen in tendons and ligaments aligns
to form parallel bundles, whereas concentric weaves are the preferred structure for bone
and blood vessels, basket weaves are most dominant in the skin and orthogonal lattices
are the prevalent structure in the cornea [4]. Furthermore, ﬁbre orientation not only affects
the mechanical integrity, but also inﬂuences the transparency, which becomes important
for limbal tissues [5].

Genome sequencing has identiﬁed 28 distinct types of collagens in vertebrates with
distinct molecular regions affecting the alignment [6]. More speciﬁcally, segments interrupting the triple helix structure cause the helical and non-helical structure to either
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associate into ﬁbrils or sheets, or even cross-link other collagen types [7]. For example,
type I, II, III, and V group together to form long ﬁbres providing tensile strength to the tissue. Type IV, however, forms a mesh-like two-dimensional ﬁbrous networks building the
base structure of the basal lamina providing more elasticity. Collagen type IX, on the other
hand, does not associate with itself, but rather uses its protruding nonhelical domains to
cross-link other collagens, such as type II, to form proteoglycans in the matrix.[7]

Given its ubiquitous distribution throughout the human body, the application of collagen as a biomaterial in tissue engineering is highly anticipated. However, as different
3D arrangements of collagen molecules are possible, the process of replication highly
depends on the type of tissue that is being mimicked. Although the process of ﬁbrillogenesis in vivo is not fully understood yet, collagen poses a great possibility for the use in
biomedical devices. More speciﬁcally, the regulation of length, diameter and 3D organisation of collagen ﬁbrils require further investigation. [4] Fibril formation in vitro appears to
be an entropy-driven self-assembly process [8]. Experiments showed that neutralisation
of weakly acidic collagen solutions sufﬁced to reconstitute collagen into ﬁbrils [9]. Furthermore, cleaving the N- and C-terminal of the collagen precursor procollagen appeared
sufﬁcient to initiate collagen ﬁbrillogenesis in vitro [10].

1.1.2

In vitro ﬁbrillogenesis and electrochemical compaction

In vitro ﬁbrillogenesis of collagen is generally divided in two steps. The molecules must
ﬁrst be directionally aligned and then cross-linked to keep their conformity. In subsequent
steps, polymerization to a broad spectrum of biomimetic architectures is possible. Numerous methods for both steps have been reported and reviewed [11].
Of special interest are methods that provide similar structural alignment to the structure
of a biological tissue. One possibility to obtain anisotropy is subjecting the molecules to
strain during polymerization, for example by extrusion [12], gravity [13] or pressure-driven
ﬂow through microﬂuidic channels [14]. Other methods inﬂuence the alignment magnetically [15] [16] or even thermodynamically by a change in temperature [17] or pH [18]. Lastly,
electrospinning has also shown to produce anisotropic collagen constructs with the further possibility to include chemical cross-linking agents to strengthen the structure after
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alignment [19].
It is only recently, that a process has been discovered that allows the arrangement of soluble collagen molecules into highly oriented and mechanically robust rod-like bundles by
using parallel wire electrodes, titled electrochemical compaction (EC) [20]. This process
takes advantage of collagen as an ampholytic molecule. When a current is applied to a
collagen solution, electrolysis of the water molecules causes the formation of a pH gradient [21] [18]. Collagen has a net charge of -0.8 C at pH = 3 (anode) and a net charge of
+0.8 C at pH = 11 (cathode). The difference in charges causes the collagen molecules to
align and compact at their isoelectric point at pI = 8.2, where it has a net charge of 0.
So far, this fabrication process has been expanded from rods to planar electrodes to fabricate two-dimensional sheets. This way, sheets ranging from a few microns up to a few
millimetres were fabricated by adjusting the collagen concentration in solution and by
repetitive electrocompaction. Only lately, efforts have been made to attempt the formation of three-dimensional structures following the topology of the electrodes. In this way,
Kishore’s group moulded molten metal into curved electrodes to produce lens-shaped
collagen structures. Furthermore, they showed the compaction of collagen onto nasal
shaped electrodes [22]. Of further interest is the integration of particles, such as hydroxyapatite into the collagen solution to produce electrocompacted collagen composites.
[22] Practically, any ampholytic molecule may be suitable for electrocompaction.

The most protruding property of EC collagen compared to randomly cross-linked collagen is the structural alignment of the ﬁbre bundles. When compacted, bundle alignment
was shown to be similar to natural tendon and ﬁbre orientation was more directional using second harmonic generation, scanning electron microscopy and small angle X-ray
spectroscopy [20]. Furthermore, the same group showed that the tensile strength of EC
collagen had a 30-fold increase compared to randomly aligned collagen, however, only
reached half the tensile modulus than natural tendon tissue.

As mentioned before, the addition of particles or other (bio-)polymers before EC is possible and inﬂuences the mechanical properties accordingly. The incorporation of elastin
has proven to decrease the Young’s modulus signiﬁcantly, resulting in more ﬂexible collagenous constructs [23]. This way, the mechanical properties can be adjusted to match
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the native tissue and the construct may be functionalized to serve as a drug-delivery vehicle.

Once collagen is fully compacted, it is further cross-linked to improve its mechanical
stiffness. The use of riboﬂavin, combined with UV-A light treatment has become widely
used, as it increases corneal stiffness immediately after treatment. UV-light is used to
induce the creation of radicals. The presence of riboﬂavin increases the effectiveness
of UV-light inducing the formation of oxygen radicals, which in turn create covalent connections between the amino acids of collagen, namely histidine, hydroxyproline, hydroxylysine, tyrosine and threonine [24]. Several other physical treatment methods such as
gamma-ray irradication and dehydrothermal treatment have also shown a good potential [25] [26] [27] [28]. Furthermore, chemical crosslinking methods has been shown using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide– N-hydroxysuccinimide (EDC–NHS),
genipin [29] [30], glutaraldehyde [31], chromium tanning [32], formaldehyde [33], polyepoxy
compounds [34], acyl azides [35], carbodiimides [36] and hexamethylenediisocyanate [37].

1.2

Collagen as a biomedical product

Collagen has shown great potential as a biomaterial in the ﬁeld of tissue engineering. For
the use in biomedical devices, different strategies of preparation for collagen exist. For
example, the original architecture may be maintained by decellularizing the tissue. Moreover, collagen may be enzymatically solubilized into a puriﬁed solution which can then be
used to freely arrange to any shape afterwards [38] [39].

When fabricating biomedical devices, collagen is usually crafted into distinct threedimensional constructs. A prominent shape is the formation of sheets or ﬁlms with a
thickness of around 10 to 500 µm. Flat constructs have been demonstrated to serve as
barrier membranes [40] or drug-eluting sheets to treat infected tissues, such as the cornea
[41]. Moreover, these sheets may act as bandage contact lenses shielding the cornea from
the impact of the blinking eye all the while eluting a drug and lubricating the eye. In turn,
this resulted in a faster healing process, as stress from the cornea surface was relieved
and a longer contact time with the eye was reached [42].
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Collagen has also been demonstrated to be swollen and stabilized into the shape of a
sponge. These constructs showed to be applicable to burn wounds, as they absorb a
great amount of exudate while adhering to the wet wound and providing a shield against
mechanical impacts and bacterial infection [43]. Finally, collagen has also been reported
to be used as a gel for subcutaneous injection [44] or nanoparticles to deliver drugs with
a large molecular weight [45].

1.2.1

Commercially available products

With fast advances in the technology, many companies have developed off-the-shelf solutions that follow GMP lines and are subjected to FDA approval.
These include readily processed sheets, sponges or similar matrices (Collagensolutions, USA) which were designed to be cut to the desired size on request. For example,
patches for dermal substitutes, such as Endoform have been developed to provide an inﬁll
for larger or even chronic wounds (Endoform, Mesynthes, NZ). Similarily, wound dressings have been developed that transform into a gel upon contact with wound exudate to
maintain a moisturized environment and cushion the wound during healing and closure,
such as ColActive, Puracol, Mediﬁll, Biostep, Woun’Dres, Dermacol (ColActive). Analogous wound dressings exist for oral wounds after dental surgery (HeliPLuG).

Collagen lenses and nerve conduits
In this research, we have successfully compacted collagen along curved and tubular templates. The matrices gained from this procedure were geometrically suitable for the application in collagen lenses and nerve conduits.
Previous work showed that collagen was used to fabricate corneal shields, serving as
pre-corneal drug reservoirs. Such lenses have shown a to deliver a 100-200-fold higher
concentration of prednisolone acetate in the cornea after 120 minutes, when compared
to topical administration through eye drops [46]. In hydrogel contact lenses, pharmacokinetics of the drug release were reportedly not reproducible, as the drug pathway was more
pronounced around the edge of the lens and highly depending on tear ﬁlm production [47].
Overall, collagen lenses were found to give a superior delivery of drugs and have shown
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no evidence of bacterial adhesion most likely due to continuous dissolution [48]. Cornea
shields reﬂective of the above-mentioned advantages have been brought to the market,
such as Soft Shield (Oasis Medical, USA), Bio-Cor (Bausch and Lomb, USA), Medilens
(Chiron Ophthalmics, USA) and ProShield (Alcon, USA).
Typically, off-the-shelf products for nerve conduits are shaped as cylindrical tubes with
channels or an internal matrix with porous walls for nutrient exchange [49]. Several FDA
approved products make use of this entubulating approach. Examples involve NeuroFlex
(Stryker, USA) and NeuroMatrix (Stryker, USA), who have both shown the repair of nerve
gaps smaller than 2.5 cm [50]. NeuroMend (Stryker, USA) has shown to prevent the migration of ﬁbroblasts while still allowing the diffusion if nutrients, reducing inﬂammation
[51]. Of interest is the inclusion of neurotrophic factors, such as NGF showing success in
guiding neuronal growth within electrospun meshes [52].

1.2.2

Safety concerns

Typically, the collagen used in biomedical devices stems from animal sources. Concerns have emerged about the possibility of transferring diseases, such as spongiform
encephalopathy through biomedical products [53]. Even though adverse reactions are
rare, IgE-mediated allergic reactions have been reported after topical application [54]. Recombinant production systems using both eukaryotic and prokaryotic hosts have proven
to be an alternative collagen source [55].

1.3

Aims of this research

In this research, we aim to demonstrate the advantages of having a highly customizable
system able to electrochemically compact collagen into a broad range of shapes applicable to tissue engineering. More speciﬁcally, we show the development of a system that
can be additively manufactured to provide patient- and tissue-speciﬁc collagen structures.
We show the compaction of collagen into ﬂat disks, lens-shaped cornea patches and ﬁnally tubular constructs that can be continuously compacted during extrusion. Constructs
created this way, are crosslinked using Riboﬂavin and UV light. Patches and lenses are
developed towards limbal regeneration, whereas collagen tubes are geared towards the
use as nerve conduits. The constructs are characterized with regards to transmittance,
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water content and the rate of degradation. Constructs are mechanically tested to evaluate whether the method of electrochemical compaction resolves not stronger gels. Lastly,
the cellular response towards the constructs is assessed using cornea epithelial cells and
PC12 cells.

Statement of Signiﬁcance
Collagen shows great beneﬁts as a scaffold material for tissue engineering and the use
in biomedical devices. Its ubiquitous presence throughout tissues of mainly mechanical
function make it a powerful biomaterial with a range of use-cases.
However, when fabricated into a hydrogel, it does not exhibit the mechanical strength that
is desired when recreating biological environments. To make collagen constructs more
processable, we utilise electrochemical compaction, causing the collagen molecules to
converge to their isoelectric point within a solution which compacts and aligns ﬁbres into a
denser construct. Three-dimensional samples created in such a way are then cross-linked
using Riboﬂavin and UV light to further strengthen the structure. Using this technique allows to signiﬁcantly improve the mechanical properties.

In this work, the fabrication of collagen constructs in 3 distinct shapes, namely ﬂat
disks, curved lenses and continuous tubes, has been demonstrated. The challenges were
two-fold. On the one side, a highly customizable electrode platform had to be developed
that allowed for fast iterations of the design. On the other side, the EC of tubes proved
to be a major step forward in fabricating cylindrical collagen constructs with a high mechanical stiffness.
The chambers were generated parametrically upon insertion of the desired parameters.
Using rapid prototyping techniques, they can be manufactured and used within hours.
This allows the fabrication of patient- or deﬁcit-speciﬁc shapes to create a perfect ﬁt.
3D constructs created in such a way can be used as patches or pain relief shields for
the cornea. Moreover, tubes may serve as conduits for nerve repair, act as a scaffold
for vessel formation or possibly even as a pressure relief structure in glaucoma patients.
Biomedical devices may serve as drug- or cell-delivery vehicles which will slowly degrade
within the body, opening up a wide range of applications for biofabrication.
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Chapter 2

Material & Methods
Experimental plan
The aim of this research was the development of functional chambers to EC collagen
into three distinctive shapes, namely ﬂat disks, curved lenses and hollow tubes. After the
design and development of the platform, suitable parameters for EC must be found. Next,
the so produced constructs must be mechanically and physiologically characterized and
ﬁnally, cytocompatibility towards limbal and neural lineages must be met.

2.1
2.1.1

Material preparation
Bovine Collagen Type I solution

Bovine collagen I solution (Nutragen, 5010-50ML, Advanced BioMatrix, USA) was diluted
to 3 mg/mL Milli-Q water on ice. The solution was then transferred into a dialysis tubing
cellulose membrane (Sigma-Aldrich, D9652-100FT, USA), which was subsequently submerged in cold Milli-Q water. Dialysis was carried out on a stir plate at 4° C over the
course of 24 hours, with 3 intermittent water changes. The solution was stored at 4° C.

2.1.2

Riboﬂavin / 10x PBS solution for crosslinking

A 1 mM Riboﬂavin/10x PBS solution obtained as follows: 37.6 mg Riboﬂavin stock (R950425G, Sigma) was diluted in 10 ml Dimethylsulfoxid (DMSO) (D1435, Sigma) at 60° C on a
stir plate to receive a 10 mM solution. Next, 10 mL of the 10 mM riboﬂavin/DMSO solution
were added to 90 mL 10x PBS. Lastly, the solution was sterile ﬁltered (Millex-GP, 0.22 µm,
Millipore, Ireland) and stored at RT protected from light.
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Electrode and chamber fabrication

The electrodes and their chambers were designed in SolidWorks 2018 (Dassault Systèmes, USA). Magics (Materialise, Belgium) was used to ﬁx minor issues in the .STL ﬁles
and to generate support structures.

2.2.1

Electrode fabrication for EC chambers

Electrodes were 3D-printed on a Realizer SLM50 (Realizer GmbH, Germany) in titanium.
The ﬁles were sliced with a layer thickness of 25 µm and exported as a F&S ﬁle using Materialise Magics. The build plate was populated in ROperator (Realizer GmbH, Germany).
After printing, parts were removed from the build area and sandblasted to remove the bulk
of the surface coarseness. The parts were then mounted on a mill (Sherline 4410, USA),
smoothened with a ﬁle and ﬁnished using sandpaper. The screw thread of the ﬂat and
curved electrodes was cut using a tap and the inner surface of the tubular electrode was
smoothened using a drill bit.

2.2.2

Chamber fabrication

Flat and curved chambers to house the electrodes
The parts were printed with a matte ﬁnish using MED610 (Stratasys, USA) and VeroWhite
(Stratasys) on an Objet Connex 350 (Stratasys, USA) After printing, the parts were cleared
of any support material and brushed clean under water.
Tubular compaction chamber to house the electrodes
The housing for the tubular electrode was printed on a Form 2 (Formlabs, USA) using
their clear resin (FLGPCL04, Formlabs, USA). After printing, the support structures were
removed, the print was washed in an Isopropanol bath (Form Wash, Formlabs, USA) for
10 min and cured for 45 min in a rotating UV chamber (Form Cure, Formlabs, USA).

2.2.3

Assembly of the EC device

The ﬂat and curved electrodes were press-ﬁt into the chambers. Pre-crimped cables were
screwed in the bottom ﬁtting and a rubber spacer was cut from Viton A 70 (Reglin Rubber, Australia) on the laser cutter (PLS6MW, Universal Laser Systems, USA). M3 nuts and
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screws were used to hold the top and bottom part together. For the tubular compaction
chamber, a metallic needle gauge 23 was press ﬁt into the housing. The 3D-printed electrode was pushed into the notch in the housing and M3 screws and nuts were used to
tighten the housing. Laser cut rubber was used as a non-conductive spacer material in
between the 2 electrodes, but also served as a septum keeping the collagen from leaking
into the housing. Electricity was supplied through the two holes in the housing.

2.3

Fabrication of EC collagen constructs

2.3.1

Electrochemical compaction of collagen

EC of ﬂat and curved collagen constructs
The hollow part of the chamber was ﬁlled with cold collagen solution and closed with its
respective top part. The side that collagen is desired to compact to was faced downwards
on a ﬂat surface and connected to the anode of the power supply. 4 V were applied for 30
minutes.
EC of tubular collagen constructs
For the tubular setup, a 1mL syringe was ﬁlled with cold collagen solution and placed
into a syringe pump (Legato 180, kdScientiﬁc, USA). The housing for the electrodes was
clamped into a tripod and the 3D-printed tubing was connected to the outlet of the syringe.
The inner needle was connected to the anode. Before compaction, a multimeter (Fluke
117, USA) was used to ensure the two electrodes did not touch. Lastly, a ﬂow rate of 4
µL/min was set and collagen was injected in between the two needles, where a voltage
of 4 V was constantly applied until the syringe was empty.

2.3.2

Post processing EC collagen structures

After compaction, the structures were submerged in riboﬂavin / 10x PBS solution over
night at 37°C (see subsection 2.1.2). Then, the constructs were subjected to UV light
(OmniCure Lx400+, Lumen Dynamics, Excelitas, USA) for 1 minute each. The constructs
were then kept in 1x PBS to wash out the riboﬂavin at RT.
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The viscoelastic properties of the collagen matrices were assessed using a parallel plate
rheometer (AR G-2, TA-Instruments) at 37°C, ﬁtted with cone-plate geometry (cone diameter: 15 mm, angle: 2°, gap: 55 µm). The acquired data was processed using Rheology
Advantage Data Analysis software. The material’s viscoelastic response was measured
using a strain sweep at 1 Hz from 0.1 to 10% of strain to identify both the storage modulus
(G’) and loss modulus (G”). Results were compared to values for collagen gels from the
literature.

2.4.2

Transmission of UV-Vis light through EC constructs

UV transmittance was measured in a UV spectrophotometer (UV-1800, Shimadzu, Japan).
Flat EC constructs were deposited on glass slides and measured against water from 380
to 800 nm. For the analysis, the transmittance absorbance of the glass slide was subtracted from the transmittance of the sample.

2.4.3

Water content of EC samples

Collagen solution was electrochemically compacted to a sheet using the ﬂat compaction
chamber described in 2.2.3. The sample was weighed after compaction and subsequently
lyophilized. The remaining construct was weighed again to determine the water content
of the sample.

2.4.4

Degradation of EC collagen over time

To assess the degradation rate of the compacted constructs, samples were incubated
in DMEM and their dry-weight was measured subsequently. Flat compacted constructs
were prepared following section 2.3.1 and submerged in DMEM at 37°C after cross-linking.
The ﬁrst sample was immediately lyophilized (Christ Alpha 2-4 LP+, Germany) to gain an
initial weight after compaction. Further samples were lyophilized after 1, 4, 7 and 14 days.
DMEM was changed every 2-3 days.
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Morphology and ﬁbre alignment of EC collagen constructs

Optical microscopy of EC collagen
Samples were monitored under light microscope (Axiovert 40 CFL, Zeiss, Germany) after
compaction without further preparation.
Scanning electron microscopy (SEM) of EC collagen
SEM (JSM 649OLA, JEOL, Japan) was performed to determine the alignment of the collagen ﬁbres after compaction. The collagen samples were washed in distilled water for 10
minutes and dehydrated in an ascending series of alcohol concentrations. The samples
were submerged in 50%, then 75%, then 90% and ﬁnally in 100% ethanol for 10 minutes
respectively. Subsequently, the samples were soaked in Hexamethyldisilazane (HMDS)
for 30 minutes and air dried in a fume hood. Samples were the coated with gold on an
SEM sample stub in a sputter coater and subsequently imaged at an acceleration voltage
of 15 kV.

2.5

Cell lines and culture conditions

2.5.1

Human cornea epithelial cells (hCECs)

Cultivation medium consisted of DMEM/F12 + HEPES (D8062, Sigma) with 10% FBS, 100
U/mL, 10 ng/mL Endothelial cell growth supplement from bovine neural tissue (E2759,
Sigma) hCECs were received from RIKEN cell bank (RBRC-RCB2280, China) and cultivated
in T25 culture ﬂasks at 37°C and 5% CO2 . Upon reaching 80% conﬂuency, cells were split
1:5 using trypsin (25200-056, Invitrogen).

2.5.2

PC12 cells

Proliferation medium consisted of DMEM (Life Technologies, USA) with 10% horse serum
(16050-122, Invitrogen, USA), 5% fetal bovine serum (FBS) (1099141, Invitrogen), 2 mM
L-glutamine (2503081, Life Technologies, USA) and 100 U/mL Penicillin/Streptomycin
(15140122, Invitrogen). Differentiation medium consisted of DMEM with 1% horse serum
(Invitrogen 16050-122) and 50 ng/mL neural growth factor (NGF) (Invitrogen, 132900-010)
PC12 cells were cultivated in small culture ﬂasks (T25, Cellstar, Greiner, Germany) in PC12
proliferation medium at 37°C and 5% CO2 . Upon reaching 80% conﬂuency, cells were split
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1:4. When seeding the cells onto the collagen constructs, proliferation medium was used
for the ﬁrst 24 h of cultivation and was then substituted with differentiation medium.

2.5.3

Seeding EC collagen constructs

The ﬂat and curved samples were seeded with 10,000 cells per EC sample. The ﬂat samples were cultured on the bottom of 12-well plates, whereas the curved collagen lenses
were cultivated within the metal compaction electrodes, held in place by a custom holder
in a 12-well plate. The tubular structures were seeded with a total of 10,000 cells per construct and cultured on the bottom of a 12-well plate. Cells were injected into the tubes
using 1 mL Ultra-Fine Insulin syringes. To promote cellular attachment, the constructs
were left to incubate at 37°C and 5% CO2 with just enough medium to keep the collagen from dehydrating. After 4 hours, the constructs were submerged in 2 mL of culture
medium. Medium changes occurred every 2-3 days.

2.6

Histological analyses of EC collagen constructs

Cell viability of hCECs on EC collagen constructs
Live and dead staining was performed using Calcein AM (C3099, Invitrogen) in DMSO
and Propidium iodide (P4864, Sigma). The cell culture medium was ﬁrst replaced with a
2 µM Calcein in PBS solution and incubated at 37°C and 5% CO2 for 15 minutes. Then,
1 µg/mL calcein solution was added to each to each well and incubated for another 5
minutes. After replacing the staining solution with PBS, the samples were imaged under
the ﬂuorescence microscope (Imager.A1m, Zeiss, Germany).
Fluorescent β -III tubulin staining of PC12 cells
Before the staining, the constructs were washed with PBS and ﬁxed in 300 µL 3.7% paraformaldehyde for 20 minutes at RT. After washing off the ﬁxing agent with PBS, the cells were permeabilized with 100 µL methanol: acetone (50:50) on ice for 5 minutes. Subsequently, the
cells were washed in PBS twice and blocked with 10% donkey serum (S30-100ML, Merck)
with 0.1% (w/v) Tween-20 (P2287, Sigma, USA) in PBS at RT for 1.5 hours. The primary
antibody, anti-β -III tubulin (MMS-435P-250, Covance, USA) was diluted 1:1000 in blocking solution and incubated at 4°C over night. The constructs were then washed with PBS
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twice for 20 minutes and incubated with the secondary antibody, Alexa Fluor 546 antimouse (A10036, Life Technologies), which was diluted 1:1000 in blocking solution, for 1
hour at 37°C. The constructs were washed with PBS three times for 20 minutes each. In
the last step, the nuclei staining (D1306, Invitrogen) was applied. The staining was diluted
1:1000 in PBS and applied for 5 minutes at RT. After washing the constructs in PBS, the
constructs were imaged with a ﬂuorescence microscope and with a confocal microscope
(TCS SP5 II, Leica, Germany).

Chapter 3

Results & Discussion
3.1
3.1.1

Electrocompaction to ﬂat patches and curved lenses
Chamber design and development

The chambers were designed to hold two electrodes in the centre and contain the collagenous solution for EC. A rubber spacer was placed between the electrodes to electrically
isolate the electrodes and provide a seal for the liquid after tightening the screws (ﬁg. 3.1).
The device was designed parametrically to follow the dimensions of the ﬁnal construct.
In other words, once the dimensions of the desired collagen construct were entered in
the CAD model (ﬁg. 3.2a), the electrodes, the spacer and the surrounding chamber were
automatically dimensioned and generated to produce the desired collagen construct (ﬁg.
3.2b). The deﬁning dimensions of the disk-shaped patches were the diameter and the
height. For the lens, the dimensions followed the prescription ﬁgures of contact lenses:
Base curve described the curvature of the lens, diameter the width and ﬁnally the lens
thickness. Using parametric design concepts allowed to change the design instantly and
produce the desired chamber within hours. This step added greatly to the customizability
of the design. Interactive 3D models of the chambers can be seen in A.1 and A.2.

3.1.2

Fabrication of EC patches and lenses

Collagen constructs were compacted at 4 V DC (ﬁg. 3.3). As can be seen in ﬁgure 3.4, the
higher the applied voltage, the higher the initial starting current, which in turn generated
the pH gradient quicker. Even though the curves start to level off faster with a higher
voltage, it is important to allow 20 to 30 minutes for the process, otherwise construct will
not be fully compacted and dissolve when soaking in cross-linking agent. A similar time
18
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Figure 3.1: EC chamber forming ﬂat and curved collagen constructs. (A) Concept of two
electrodes forming a lens (B) Assembly of lens compaction chamber and (C) its electrodes. (D) Flat compaction chamber and (E) its electrodes.

Figure 3.2: (A) Screenshot of the parameters used to design the lens in SolidWorks. (B)
Technical drawing of the resulting lens.

frame is required when gelling collagen to a hydrogel [56].
As prolonged subjection to higher voltage induces the formation of bubbles, it is best
to use a lower voltage, around 3 to 4 V, and 30 minutes of compaction to obtain fully
compacted and stable constructs without bubbles. When soaking the samples in crosslinking solution, we found that samples should remain in the compaction chamber itself,
as submersion in a large volume of solution may cause the constructs to dilute. Figure
3.3 shows an EC disk patch after being cross-linked. The constructs were strong enough
to be handled with tweezers and spatulas and the thickness can either be adjusted by
changing the collagen concentration or the initial height of the chamber.

Cheng et al. have initially reported the wire electrode for the compaction of collagen
[20]. In their setup, 2.5 V DC at 3.5 µA were applied for 1 hour, resulting in an electric ﬁeld
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strength E of 2.5 kV/m (deﬁned as E=V/d, whereas V is the voltage and d the gap between
the two electrodes). In comparison, the ﬂat EC chamber in this study had a potential
ﬁeld strength of around 4 kV/m, when run at 4V with an initial mean current of 14 µA for
30 minutes and a distance d of 3 mm. Both, ﬂat and the curved chambers, allowed an
instant deposition of collagen molecules onto the electrode, forming three-dimensional
constructs in a short time frame.

Figure 3.3: Flat collagen patches (A) top view (B) side view

Figure 3.4: Current drawn over time when EC collagen at different voltages
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Chamber design and fabrication
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To fabricate hollow tubes, collagen must be shaped upon extrusion. An initial experiment
featured 2 needles held concentrically in opposing directions (ﬁg. 3.5a). Upon extrusion of
collagen, the molecules compacted onto the inner needle (ﬁg. 3.5b). While the experiment
conﬁrmed the feasibility, this setup did not provide a scalable method as the process had
to be stopped once the inner needle was fully covered.
In the next iteration, an extrusion head was desired that could continuously extrude onto
a plate. For this, the needles had to face the same way to provide an opening for the collagen tube to dispense out.

The ﬁnal design of the tubular compaction device featured a stainless-steel needle as
the inner electrode, held in place by a non-conductive 3D-printed chamber using SLA. The
chamber featured a notch to insert an outer electrode that enclosed the needle concentrically. The two electrodes were electrically isolated with a rubber spacer that also acts
as a septum directing the collagen downwards. Collagen solution is fed through an inlet
into the void between the two electrodes with a syringe pump and is compacted onto the
inner needle (ﬁg. 3.6a and 3.6b). An interactive 3D model can be seen in A.3. The resulting tube was very fragile and would easily stick to itself and close off the inside when not
supported (ﬁg. 3.6e). Therefore, the last iteration of the chamber featured a 10 cm long
needle protruding from the nozzle for collagen to compact onto. With such a long needle,
only the top half of the needle is surrounded by the outer electrode providing a tubular
cavity for the collagen to be compacted into (ﬁg. 3.6c and 3.6d).
This allows the formation of a very long tube supported by the inner needle after compaction until fully cross-linked. Initially, the central needle was thought to be able to deliver
the cross-linking solution by soaking the compacted tube from the inside directly after
compaction. However, when the compacted part was soaked in PBS/Riboﬂavin solution,
ions form the cross-linking agent continued to diffuse upwards into the non-compacted
collagen solution, effectively shorting the circuit between the two electrodes and bringing
the compaction process to an end.
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Figure 3.5: Preliminary experiment showing the feasibility of tubular EC (A) Two needles
held in place concentrically served as electrodes forming a tubular caveat for the collagen
to compact in (B) close-up of the EC collagen tube
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Figure 3.6: Tubular compaction chamber: (A) colour coded render: green: outer chamber
(one part), gold: inner needle (short version), black: rubber septum, copper: outer electrode (B) colour coded render of cross-section (C) 3D-printed chamber (open) holding the
central needle and outer electrode (D) chamber when closed (E) EC collagen extruding
onto needle (old model with short needle)

3.2.2

Fabrication of the collagen tube

The ﬁnal chamber allowed compaction of collagen at 7 V and a speed of 4 µL/min, yielding
continuous tubes with a wall thickness of around 300 µm (ﬁg. 3.7). The solution was fed
into the electrodes with a syringe pump and the potential was applied instantly, without
waiting for the caveat to ﬁll up completely ﬁrst. This method allowed the most reproducible outcome as EC started immediately and the nozzle did not clog. Other methods
were tried where the nozzle would be pre-ﬁlled with collagen before applying a current
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and initiating the ﬂow. Also, ﬁlling the nozzle and waiting for it to fully compact before initiating the ﬂow from the syringe pump was tried. However, unless the syringe pump was
turned on at the exact right moment, both latter methods resulted in either uncompacted
collagen or clogged the nozzle.

A major caveat of this methodology was the printing speed. To improve the speed, multiple ways were investigated. At 7 V, the extrusion speed was limited to 4 µL/min, which
takes more than 4 hours for the formation of a ∼1.5 cm tube. Higher extrusion speeds
resulted in the malformation of the tube, as the collagen was still liquid when leaving the
outer electrode, suggesting incomplete compaction. However, as seen in in ﬁgure 3.4, a
higher voltage formed the electrochemical gradient faster. Although this suggests that
the collagen should compact faster, we have seen that ﬂat disks that were not given 2030 minutes to form, were not fully compacted either and dissolved in the cross-linking
solution, hence, an increase the voltage would not automatically allow a faster extrusion
speed.

Another way to improve the speed involved changing the design of the outer electrode.
As the ﬁnal iteration involved a central needle protruding far out from the outer electrode
to collect the compacted collagen, the outer needle could also be elongated. At the same
extrusion speed, this would result in a longer contact time between the two electrodes.
Hence, the extrusion speed could be increased to revert to the original contact time that
yielded the tubes described in this study. In other words, a longer outer electrode would
result in a longer period of contact and therefore extrusion speed could be increased.
However, in our case, the nozzle was fabricated on a ReaLizer 50 machine, which has
a maximal printing height of 75 mm, limiting the in-house production of a longer outer
electrode.
Finally, the print speed could be optimized by varying the collagen concentration. However, by reducing the collagen in solution, thinner tubes would be fabricated that may not
suit the desired application.

Another challenge revolved around the water secretion stemming from electrochemical compaction. As the collage compacts at its isoelectric point, the volume around it is
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composed of the left-over water. In a ﬂat chamber this water can be removed after the
process. However, when using a continuous process, water needs to have a way of escaping constantly. In our case, water would drain out of the nozzle at the beginning of
the process, and, at times, this may have disrupted the compaction process, as it carried
off partially compacted collagen from the construct. In the preliminary experiment, water
drained off towards the bottom, whereas collagen compacted sideways onto the needle
(ﬁg. 3.7b). This electrode setup was thought to potentially serve as a collagen printhead
for bioprinting. For this case, further design iterations need to be undertaken.

Figure 3.7: EC collagen tube (A) overview (B) tubular opening (C) cross-section to measure the diameter and thickness

3.3

Characterization of EC constructs

3.3.1

Light transmission through EC constructs

Flat EC constructs have shown 85 to 90% light transmission within the visible light spectrum (400-800 nm) (ﬁg. 3.8). Comparable results were reported in the literature, where EC
collagen matrices were shown to have 70-85% light transmission between 400 and 700
nm after crosslinking with EDC-NHS [57]. Beems et al. have obtained similar results when
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measuring the light transmission of the cornea in human eyes by implanting a photodiode
in the anterior chamber of donor eyes. Results indicated that light transmission between
was ranging between 80 to 96% in the same spectrum [58].
As mentioned previously, the prolonged compaction beyond 30 minutes may result in the
formation of small bubbles, which will have an impact on light transmission of constructs.

The main factor inﬂuencing light transmission of the constructs is the alignment of the
collagen ﬁbres. It was reported that transparency in vivo is inﬂuenced by ﬁbrillar growth
and spacing, which in term is modulated by keratinocytes [59]. Of further interest is that
the light transmission of EC collagen constructs increased signiﬁcantly after keratocyte
culture [57].
Given the above information, it may be possible to enhance transparency by optimizing the
parameters for EC. For the potential use as a drug- or cell-delivery system for the cornea,
a transparency of 85 to 90% is however acceptable for temporary patches.

Figure 3.8: Light transmission of EC collagen patches in the visible spectrum
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Degree of compaction, water content and passive degradation of EC constructs

Flat EC collagen matrices were measured after compaction and averaged to a thickness
of around 1.4 mm. Compared to the initial height of the ﬂat compaction chamber of 3.1
mm, this concludes a compaction of 45%. In other words, compacted constructs were
2.2 times denser. The thickness of tubes was averaged to about 300 µm (ﬁg. 3.7c) with
a gap of 400 µm between electrodes (ﬁg. 3.7b). EC collagen sheets were reported to be
17 times denser when compared to collagen gels [22]. Results differed by almost an order of magnitude, as we compared the EC constructs to the initial height of the solution.
Moreover, the EC constructs in this study were not measured directly after EC, but after
swelling, which may further increase the thickness.

The water content of compacted ﬂat collagen patches was gravimetrically determined
to be around 96%. Uncrosslinked EC collagen was reported to have a water retention capability of 87%, whereas crosslinking with EDC-NHS lowered the value signiﬁcantly (p<
0.05) to 65% [57]. As a comparison, cornea from rabbit eye was reported to have a water
content of 77.8% [60], however, water contents of hydrogels are generally upwards of 90%.
A high water content can act as a larger drug reservoir, indicating the potential use of EC
collagen as drug-delivery vehicle [61]. Such a device could play a major role in scar-free
recovery of the cornea after surgery [62]. Furthermore, they provide major advantages
over eye drops, as they slowly elute drugs hence prolonging the time the drug is in contact with the surface. While some have reported the inclusion of microparticles into the
collagen during EC [22], others have found that soaking collagen shields in the desired
drug is sufﬁcient to treat ocular viral infections, such as herpetic keratitis [63].

EC collagen constructs were found to gradually degrade over time, when cultivated in
DMEM (ﬁg. 3.9). Constructs appeared still intact after two weeks. Compared to results
from the literature, EC collagen was reported to lose half of their initial mass in less than
2 hours [64] and were fully degraded after six hours when cultivated in collagenase [57].
Collagen shields from Bio-Cor (Bausch and Lomb, USA) have dissolution times of 12, 24
and 72 hours in which they constantly lubricate the eye. It has also been reported that the
degree of UV-induced cross-linking has an inﬂuence on the dissolution time [65].
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Figure 3.9: Passive degradation of EC collagen in DMEM over 14 days

3.3.3

Rheological characterisation of EC constructs

Rheology of EC collagen showed a storage modulus (G’) in the range of 230 Pa and a
loss modulus (G”) of around 25 Pa in the range of 0-10 % strain (ﬁg. 3.10). The ratio of
G’ to G” is a measure of internal friction, in this case the collagen sheet is far more elastic than viscous. Results published by Yango et al. suggested that non-EC collagen at a
similar concentration has a storage modulus and a loss modulus ranging by an order of
magnitude lower compared to our data of EC collagen [66]. Of note, another group has
published similar results for the two moduli and suggest that collagen hydrogels undergo
changes in their mechanical properties after prolonged cold storage. More speciﬁcally,
collagen gels show lower values for both G’ and G” after being stored at 4°C. This data
suggests that we see a signiﬁcant increase in storage and loss moduli between EC and
non-EC collagen. Furthermore, storage conditions after compaction may have affected
the moduli of EC collagen constructs.

EC constructs were reported to have a high stiffness, with a Young’s modulus of 0.24
MPa [64] and tensile modulus of around 1.8 to 1.9 MPa when crosslinked with EDC-NHS
[57]. For the measurement of the Young’s modulus, compacted constructs had twice the
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concentration than in this study.
Comparable results were tried to be obtained for the EC collagen patches and lenses,
however, nanoindentation would not deliver a reliable measurement due to the load cell
being out of range, which is the reason for not including compression data in this thesis.

Figure 3.10: Storage (G’) and Loss Modulus (G”) of EC collagen after crosslinking between
0 and 10 % strain

3.3.4

Morphology and ﬁbre alignment of EC constructs

Optical microscopy and SEM images were acquired to determine an overall directional
alignment of ﬁbres in EC collagen constructs. Figure 3.11 a depicts the cross-section of a
ﬂat collagen patch immediately after compaction and ﬁgure 3.11 b shows the surface of a
tube. Both pictures conﬁrm the presence of tightly packed and highly aligned ﬁbres, with
the cross section showing ﬁbre alignment throughout the whole depth of the constructs
parallel to the two electrodes. SEM images were taken top-down onto the samples. Fibres in both, the ﬂat (ﬁg. 3.11 c) and the tubular construct (ﬁg 3.11 d) appear to be closely
packed and horizontally aligned. Overall, electrocompaction induced a high level of ﬁbre
alignment parallel to the electrodes regardless of the desired shape, which coincides with
results reported from other groups using EC [20] [22].
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Samples for SEM were prepared by dehydration, which may have caused the construct
to shrink. It appeared that the shrinkage induced ridges, that follow a directional alignment. However, as the formation of ridges generally follows the alignment of the underlying ﬁbres, this directional alignment of the ridges may further conﬁrm the alignment of
collagen ﬁbres. Of note, impurities of the surface of the tube (ﬁg. 3.11 d) stemmed from
debris from the storage and preparation of the sample.

Figure 3.11: Morphology of EC collagen constructs (A) cross-section of disk-shaped
patches immediately after compaction (B) hollow tube after cross-linking and soaking
in PBS for 24 h (C) SEM of disk patches (D) SEM of tubular construct (debris stems from
storage)

3.4

Using EC collagen constructs as a medical device

3.4.1

Flat patches and curved lenses

To assess the feasibility of the constructs as a cell delivery vehicle, cornea epithelial cells
were initially seeded onto ﬂat patches for 3 days to test the cytocompatibility of the constructs. Subsequently, a cultivation period of 17 days was chosen on the curved lenses to
show the effects of long-term cultivation . When cultured on curved lenses, epithelial cells
showed a viability greater than 90% after 3 days of culture (ﬁg. 3.12 a) (N = 1). Prolonged
culture of cornea epithelial cells for 17 days on the ﬂat disks yielded a cell viability greater
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than 99% (N = 1). Apoptotic cells (ﬁg. 3.12 b) may stem from a lack of nutrients related to
their position underneath the collagen construct.

These results indicate that collagen, albeit highly compacted, provided an ideal environment for cell culture. Moreover, as discussed by Kishore et al., EC collagen promoted
cellular attachment and proliferation in mesenchymal stromal cells compared to uncompacted collagen due to its greater mechanical stiffness [67].

Both shapes could prove highly useful for the use in limbal tissue engineering. For
example, for DMEK, when Descemet’s membrane is transplanted without its adjacent
stroma. Handling this thin and fragile membrane proved to be a challenge in the clinic
and as a result, the transplants suffered from great cell loss which ultimately lead to a
higher post-operative detachment rate when compared to DSEK [68]. Using the EC collagen patches as scaffolds during transplantation could provide a solution, as the ﬂat EC
patches can be fabricated into thin, optically clear biocompatible scaffolds for the membrane to rest on during transplantation.

In a similar way, the curved lens could be used as a corneal lens shield, providing ocular
comfort after surgery. The devices could protect an injured cornea from the harsh friction
caused by the movement of the eyelid and hence aid the healing process. Moreover, they
aid in lubricating the eye as they dissolve, relieving the patient from dry eyes [69]. The
main advantage of our EC constructs is the customizability, allowing the formation of
patient-speciﬁc cornea shield that provide an ideal ﬁt for the human eye.

Similar approaches to generating curved collagen lenses have recently been demonstrated, such as bioprinting cell-laden hydrogels into a curved mould. For this, composite
hydrogels consisting of sodium alginate and methacrylated gelatine, mixed with corneal
keratocytes were extruded and crosslinked into a curved shape [70]. However, extrusionbased systems subject cells to higher shear rates causing deformations. Moreover, the
viscosity of the hydrogel required the use of a mould to keep the shape of the lens. In comparison, EC is superior to extrusion-based systems when highly viscous solutions need
to be processed, however extrusion-based systems allow the direct incorporation of cells
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during printing.

Figure 3.12: Live (green) / Dead (red) staining of human epithelial cells (A) Curved lensshaped construct after 3 days of culture (B) Flat disk patches after prolonged culture of
17 days. (N = 1)

3.4.2

Collagen tubes

Using the tubular construct as a scaffold as a nerve conduit was demonstrated using
PC12 cells, a cell line derived from mural adrenal glands. A characteristic of the cell line
is the induction of its neuronal phenotype when subjected to neural growth factor (NGF).
EC tubes were seeded with cells and cultured with NGF for a total of 10 days. After 24
hours, the ﬁrst neurites were visible (ﬁg. 3.13 a). After 7 days, neurites were visibly interconnecting cells to aggregates (ﬁg. 3.13 b). After 10 days, the constructs were stained for
β -III-tubulin to visualize the microtubules of neurons.
Figure 3.13 c and 3.13 d show dense cell clusters that were highly interconnected by neurites on the surface of the tubular constructs. Confocal microscopy showed a neurite
network of PC12 cells along the curved surface (ﬁg 3.13 e). Furthermore, 2 clusters were
seen extending their neurites towards each other (ﬁg. 3.13 f).

PC12 were shown to align neurite outgrowth along the underlying ﬁbre alignment [71].
As shown in ﬁgure 3.11, tubular structures show longitudinal ﬁbre alignment, suggesting
cells to bridge the two ends of the tube. Figure 3.13 b suggested neurite alignment parallel
to the overall ﬁbre alignment, however, results were not quantiﬁed.

PC12 cells cultured on compacted collagen matrices not only showed similar differentiation patterns compared to non-compacted collagen gels, but also formed continuously
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growing aggregates as described in the literature [72] [73]. PC12 cells were reported to divide once more after addition of NGF before entering G0 phase, in which cells would not
proliferate anymore, suggesting that clusters were formed via cellular migration, rather
than proliferation [72].

Neurite outgrowth of PC12 cells was reported to be dependent on the substrate stiffness. The number of neurites was reportedly higher on stiffer substrates and the amount
of branching correlated with the substrate stiffness. For the latter, substrates with a shear
modulus of up to 19 kPa were measured. Leach et al. concluded that a threshold of below ∼10 Pa (shear modulus) would negatively correlate with neurite growth and that the
optimal region ranged between 102 and 104 . Moreover, no signiﬁcant changes were seen
above the optimal range on ﬁbronectin matrices [74]. Gunn et al. have reported that the
Young’s modulus of the hydrogel greatly impacted neurite outgrowth. The highest growth
was achieved on PEG hydrogels with a Young’s modulus of around 200 kPa. Substrates
stiffer than 200 kPa were shown to negatively affect growth [75]. Of interest is that EC
collagen, at a concentration of 6 mg/mL was reported to be have a Young’s modulus of
around 240 kPa [64]. For our study, this suggests that using twice the concentration of
collagen would enhance the stiffness of the EC tubes and positively impact length and
branching of neurites.

The goal of using the hollow tubes was to show that EC tubes can guide and support neural cells. The hollow tube in this approach was made possible by reinforcing
the outer wall using electrochemical compaction of the structural protein collagen. Other
approaches have shown mould tube casting [76] or rolling a sheet to a tube [77]. Using the
methodology shown in this approach we want to report the formation of tubes in a single step. In addition, this method may allow the incorporation of more intricate features
into cylindrical structures, such as inner channels, making the constructs more similar to
conduits currently used in the clinic [49].
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Figure 3.13: PC12 cells on EC collagen tubes subjected to NGF (A) Neurite branching
slowly visible after 24 hours (B) After 7 days, branching clearly visible and cells appear
to form clusters (C-F) beta-III-tubulin staining (red) and DAPI (blue) after 10 days. Clear
formation of clusters and strong branching visible between clusters. (N = 1)
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Chapter 4

Conclusion & Future Outlook
In this study, we have shown the feasibility of a highly customizable platform for the EC
of collagen into 3 speciﬁc shapes. The platform can be adapted and manufactured within
hours to fabricate deﬁcient-speciﬁc solutions by forming either a collagen patch, lens or
hollow tube.
The method of electrochemical compaction of collagen has shown to produce constructs
with densely packed and highly aligned ﬁbres. As the method provides the desired constructs in a fast, easy and safe way, the platform can ﬁnd an application in a clinical setup.

Collagen constructs made using this method have shown to serve as medical devices,
supporting the proliferation and differentiation of different cell types. The above mentioned shapes have an important application in the ﬁeld of tissue engineering and regenerative medicine. While ﬂat patches and curved lenses have shown adaption for skin
wounds and corneal shields before, the most novel is the continuous fabrication of hollow tubes.
Here, we have assessed their feasibility of tubes as nerve conduits, however a broad range
of applications emerge for cylindrical constructs. Ranging from bile ducts in the liver,
to muscular tendons, all the way to angiogenesis support and even glaucoma drainage
devices, tubes are a repeating shape within the human body.
A mostly unexplored thought is the possibility to apply the design of the tubular compaction chamber to ﬁt the needs of bioprinting. With collagen as a strong biomaterial for
tissue engineering, being able to print collagen via extrusion/compaction into continuous
ﬁne tubes may pose a viable alternative to current methacrylated (bio-)polymers, which
may greatly impact the ﬁeld of bioprinting.
35
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As we have highlighted a range of possibilities for our constructs, we want to further investigate the use as a drug-delivery vehicle. While soaking the constructs is a possibility,
incorporating microparticles, that contain the drug, into the collagen during electrocompaction, will allow the fabrication of biological constructs with drug-eluting capabilities
in one step. Moreover, this will play a signiﬁcant role in improving the controlled release
in vivo and improve de novo tissue formation by providing speciﬁc biological cues. EC
also allows the inclusion of other structural elements during the process. Incorporation
of other structural (bio-)polymers, such as ECM proteins, or minerals, such as hydroxyapatite, may greatly enhance the mechanical properties. Moreover, their biological capabilities may improve greatly by providing RGD sequences or other active sites for cellular
attachment and communication.

Lastly, we want to emphasize the possibility of creating more intricate shapes. As previously mentioned, neural guides can feature internal channels. Such channels may easily
be replicated by adding more than one needle. Even more challenging shapes can be fabricated by twisting and bending the needles. More so, up- and downscaling constructs in
size is only limited by the fabrication capabilities of electrodes. Upscaling the production
of constructs is easily possible through simultaneous compaction.

To summarize, we have shown the formation of tubes, patches and lenses using EC
of collagen within a highly modular platform. EC did not have an adverse effect on cytocompatibility of collagen and showed great improvement on the processability of the
biopolymer. By sharing these results, we hope to add to collagen being used as a biomaterial for the ﬁeld of tissue engineering and bioprinting.
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Appendix A

Appendix
This section showcases the 3D models of the EC chambers used in this research. To
view the models, Adobe Acrobat Reader is required. The assembly can be rotated and
zoomed in the same way than in the CAD program. Furthermore, individual parts can be
deselected in order to revel to inner geometry of the assembly.
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A.1

3D Disk EC chamber

Figure A.1: 3D model of the disk compaction chamber
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A.2

3D Lens EC chamber

Figure A.2: 3D model of the lens compaction chamber
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APPENDIX A. APPENDIX

A.3

3D Tube EC chamber

Figure A.3: 3D model of the tubular compaction chamber
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Biofabrication double degree statement
Appended to this document is an additional annex that represents the entirety of a one-year
project undertaken at the Utrecht University and submitted as part of the fulfilment of the Double
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Abstract
Perfusion bioreactors have proven efficient in expanding cells on a scaffold in vitro for the
purpose of bone tissue engineering.
The aim of this study was to develop and investigate the use of a 3D-printed cell culture device to
obtain a perfusable and cell-laden hydrogel construct that allows for vasculogenesis, angiogenesis
and, later on, osteogenic differentiation. Therfore, a perfusable construct was developed, 3D-printed
using stereolithography (SLA), and characterized using a computational model.
Mesenchymal stromal cells (MSCs) and endothelial colony-forming cells (ECFCs) were co-cultured
in an enzymatically crosslinked gelatin hydrogel. Throughout the hydrogel, a central channel, lined
with ECFCs, allowed the diffusion of nutrients into the adjacent matrix.
Peristaltic perfusion of the channel caused an inflation and deflation of the construct, resulting in
a deforming hydrogel, causing uneven loading throughout the construct. In comparison, the use
of laminar perfusion allowed to exert a more controllable flow onto the constructs, resulting in an
ECFC-lined macrochannel, expressing VE-Cadherin on the surface. Within the hydrogel, CD31 and
α-SMA were expressed, suggesting the presence of ECFCs and the differentiation of MSCs towards
mural cells. However, the formation of a vascular bed was not seen in any of the constructs.

2
Laymen’s summary
Bone is a noteworthy organ that plays a major role in multiple fields of our everyday life, such as in
movement, protection and support of other organs. Albeit being an organ that can regenerate, defects
bigger than 6 cm pose a major problem and most certainly need a transplant surgery. Currently, the
method of treatment involves removing a piece of bone from places such as the hip and implanting
it into the defect site. Apart from involving a second surgery, the treatment can cause donor site
infections or morbidity.
Tissue engineering aims to circumvent this problem by partially regenerating the tissue outside
of the human body. This approach involves aspirating stem cells from a person, expanding them in
vitro and seeding a scaffold that aids in regrowth.
When regenerating a three-dimensional (3D) structure, such as bone, it is important to realize that
nutrients and oxygen can only diffuse for 100-200 µm. All the cells further away from the source
will suffer from a shortage and eventually die off. In nature, this problem is solved by blood vessels
throughout the human body. To regenerate a part of an organ, it is therefore important to include
vascularization within the scaffold.
Previous studies have shown that a co-culture of mesenchymal stromal cells (MSCs) and endothelial
colony-forming cells (ECFCs) induces sprouting of ECFCs into a capillary-like bed and differentiation of MSCs towards mural cells, stabilizing the newly formed microvessels. Only upon formation
of a capillary-like network, undifferentiated MSCs may be stimulated to differentiate towards the
osteoblast lineage allowing for tissue maturation and later bone formation.
In our research, we created a device that can be casted with a cell-laden hydrogel, acting as
the scaffold. This gel contained a co-culture of MSCs and ECFCs. A removable splinter created a
hollow tube through the gel. Subsequently, this channel was seeded with ECFCs with the intention
of forming a confluent layer on the surface, effectively creating a big vessel within the gel. This
macrovessel was perfused through an in- and outlet in order to deliver required nutrients and oxygen.
A monolayer of ECFCs was seen within the channel and cells survived throughout the hydrogel. Peristaltic perfusion caused inflation of the hydrogel, therefore we opted for perfusion with a
syringe-pump, exerting a more controllable flow onto the hydrogel, in later experiments. Using the
syringe-pump, we showed that ECFCs are able to line a channel even at higher flow speeds. Within
the gel, we have seen the expression of endothelial markers (CD31) and markers that showed the
differentiation of MSCs towards mural cells. However, no sprouting of a microvessel-like structures
was seen within the hydrogel.
Future research will hopefully show the sprouting of a vascular bed and the interconnection
between the macro- and the microvessel in order to perfuse the whole constructs with nutrients
and establish the developed bioreactor platform as an important step towards the regeneration of
vascularized bone tissue.

1. Introduction

Interest in the fabrication of artificially engineered tissues has experienced a rise in the past
decade. Major advancements in the field of tissue engineering (TE), such as the recapitulation of
microen-vironments and efforts to attempt vascularization, have pushed the field and hope to
address the growing need for donor organs. While whole-organ manufacturing is not achievable
yet, partial replacement that take over organ functions and take over some functionality until a
donor organ can be feasible. [1].
Bone, for example, is known to regenerate defects up to around 6cm. Once this critical size is
exceeded, an autologous graft may be needed. While this is the current standard of treatment, it also
implies having a second surgery for prior tissue collection and may cause an infection or donor site
morbidity [2].
Tissue engineering provides ways to recreate such structures without the need for a human host.
While standard 2D monolayer cell culture is widely used for cell-based assays, external cues from
the tissue-specific microenvironment may be missing, causing cells to respond differently than in
vivo. A shift towards three dimensional cell culture systems has shown the potential for recreating
more organotypical environments [3] [4]. Most notably, co-cultures provide cells with physiological
cues, such as cell-cell and cell-matrix contact, affecting cellular behavior including proliferation,
differentiation and angiogenesis [5] [6].
With added dimensionality, tissue constructs are facing a critical problem. Core parts can become
undersupplied, as nutrients and oxygen cannot diffuse through the whole thickness of the construct.
Therefore, when relying upon passive diffusion for nutrient delivery and waste removal, the size of
tissues is limited [7].
Vascularizing tissue constructs may provide a promising way of solving this problem. In short, either
a pre-formed capillary network (e.g. from decellularized tissues) may be embedded into a scaffold
or scaffolds may be stimulated to self-assemble a vascular network by endothelial sprouting and
matrix remodeling [8]. Endothelial progenitor cells (EPCs), such as endothelial colony-forming
cells (ECFC), have shown great potential in forming vasculature for tissues. EPCs can either line the
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walls of a pre-defined geometry to form vasculature or sprout into microvessel-like structures within
hydrogels by means of directed differentiation [9].
Following the first approach, hollow 3D geometries, such as tubes, are lined with EPCs. Upon
formation of a monolayer, these structures effectively create a macrovessel, which can be used to
deliver nutrients to the adjacent hydrogel [10]. Similar to microfluidics, fluid flow can then be guided
through a lined macrochannel, supplying nutrients and oxygen and transducing mechanobiological
cues to the inner surface of the channel. ECs reportedly align [11] and elongate [12] under shear
stress and ECFCs show transcriptional responses to shear stress, such as elevated levels of KLF-2
[13].
Within the hydrogel itself, the angiogenic approach is followed, where endothelial cells partially
degrade their environment, proliferate and then invade it in order to functionally reorganize into a
vascular network with the help of supporting cells, such as pericytes [8]. Encapsulated co-cultures
of ECs with mesenchymal progenitor cells have shown the formation of long-lasting blood vessel
networks, that were functional for up to one year [14]. This result is based on the ability of MSCs to
differentiate into mural cells, such as pericytes or smooth muscle cells, when in a co-culture with
ECs [15].
In an attempt to connect the two approaches, Lee at al. have reported a bioprinting technique that
facilitates the formation of a vascular macrochannel in collagen branching into a capillary network
within an adjacent fibrin gel. HUVECs reportedly sprouted from lined macrochannel into the fibrin
to extend the vascular network under static conditions [16].
Perfused tissue constructs are usually cultured within bioreactors. While, generally, three types
of bioreactor systems exist, spinner flasks and rotating wall bioreactors do not fully perfuse media
throughout a construct, and are therefore unsuited for the perfusion of a channelled construct [17].
Perfusion bioreactors allow to exert a defined amount of shear stress onto the cell walls. Studies
showed, that flow rates in the range of 0.3 -3.0 ml/min increased calcium deposition and the rate
at which rat marrow stromal cells were differentiating [18]. Additionally, it was reported that fluid
shear can induce osteoblastic differentiation of MSCS similar to dexamethasone, an induction agent
added to cell culture media [19].
For this research, a bioreactor chamber was developed and 3D-printed that allows for perfusion
of gelatin hydrogels laden with a co-culture of MSCs and ECFCs. A removable spacer was placed
through the construct to create a central channel after the hydrogel was cross-linked. This channel was
then lined with ECFCs and perfused. This way, the capability of the platform to form microvessel-like
structures within the gel and a lined macrochannel throughout the gel, was assessed, and osteogenic
differentiation was analysed.

2. Material and Methods

2.1

Experimental design
First, a bioreactor device was planned and modelled until a design was found that allowed for the
placement of a central splinter through the fluidic connectors. A casted digital model was then
characterized with regards to flow rates and resulting shear rates, using a computational model.
Subsequently, the available materials were assessed on cytotoxicity towards MSCs and the device
was 3D-printed in the most compatible material. The main scientific aim was to develop a perfusable
device that would allow for a central channel through a hydrogel for perfusion. In such a construct,
cell viability, angiogenesis/vasculogenesis and subsequently osteogenic differentiation were assessed.
Peristaltic and laminar flow types were assessed at two flow rates and compared. Samples were then
analysed for the following:
•
•
•
•
•
•
•

2.2
2.2.1

Live/Dead staining (Calcein/Ethidium homodimer)
Cell morphology (Phalloidin/DAPI)
ECFC coverage on the inner surface of the macrochannel (GFP–ECFC)
Ability of ECFC to form microvessel-like structures in a co-culture (CD31/DAPI)
Differentiation of MSCs to α-SMA+ cells (α-SMA /DAPI)
Cell-cell contact (Ve-Cadherin) and endothelial identification (von Willebrand factor)
Early osteogenic differentiation (ALP)

Fabrication of the device
Design
The device consisted of a central chamber measuring 3 x 3 x 7 mm with two barbed connectors on
opposing sides for perfusion. Throughout the whole device, including the 2 connectors, a tubular
capillary with a diameter of 1 mm was placed, serving as a placeholder for the fluid channel during
casting. The device was modelled and analyzed in SolidWorks 2017 (Dassault Systèmes, France)
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Figure 1: Creating a perfusable channel within cell-laden hydrogel. A: Bioreactor device with
central splinter B: Bioreactor device casted with hydrogel. C: After cross-linking of hydrogel, central
splinter was removed, leaving a perfusable channel. D: Cross-section of a casted bioreactor device
2.2.2

3D-Printing
The design of the microfluidic tissue device was generated in SolidWorks and exported to Magics
software (Materialise NV, Leuven, Belgium) to generate suitable support structures. Perfactory
RP (EnvisionTEC) was used to populate the build plate, slice the objects and generate the job
file with the according build style. The devices were printed from PIC100 resin in a Perfactory
3 mini multi-lens SLA printer (EnvisionTEC GmbH, Gladbeck, Germany) with a basefilm layer
and a resolution of 25 µm. The resulting prints were flashed for 3500 cycles in an Octoflash G171
apparatus (EnvisionTEC) to further cross-link any uncured resin. Lastly, the models were washed in
100% ethanol at 37◦ C for 6 hours, refreshing the ethanol every 2 hours.

2.2.3

Material toxicity
In order to choose a suitable material for the bioreactor, the available SLA-printable materials
were assessed for cytotoxicity with an Alamar Blue Assay. The tested materials for the Perfactory
3 included Pic100, R05 and E-Shell beige. E-shell clear and PR48 were printed on the Ember
(Autodesk, San Rafael, California). As PR48 was presumed very toxic, the material was assessed
after 2 different flashing cycles (2500 and 4000).
First, a calibration curve is needed to determine the optimal seeding density for the experiment.
MSCs were therefore seeded in 48-well plates at 5 densities (5000, 10000,20000, 35000 and 50000
cells) (n=3, N=1) and cultured in 500 µL MSC expansion medium at 37◦ C and 5% CO2 . After 24
hours, the medium was exchanged with pre-incubated medium to account for nutrient degradation
when testing different materials in the main experiment. 18 hours before the absorbance measurement,
50 µL of a 10x stock Alamar Blue was added to the medium in each well. 100 µL of each well
were pipetted into a 96-well plate (in duplicates) and absorbance was measured with a Fluoroskan
(Ascent, Thermo Fisher, USA) at an extinction of 570 nm and an emission of 544 nm. To test the
cytocompatibility of the different materials, 3D-printed chips of each material were incubated in
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Figure 2: Perfusion setup for bioreactor. Media reservoir (left) with tubing. Ends that will be
connected to the perfusion bioreactor are wrapped in aluminium foil for sterility reasons after
autoclaving.
medium for 72 hours. The polymer to medium ratio was chosen to be 1:4, following the ratio of the
inner surface of the bioreactor to the amount of hydrogel. MSCs were cultured in the pre-determined
optimal density of 7500 cells per 48-well in regular MSC expansion medium for 24 hours. Then,
the medium was exchanged with pre-soaked medium and cultured for another 24 hours. 18 hours
prior to the measurement, 50 µL of 10x stock Alamar Blue (B21187, Alfa Aesar, USA) was added
to each well. Samples were measured in the same way as the calibration samples. A control group
with unconditioned MSC expansion medium was used to determine 100% metabolic activity.

2.3

Perfusion Setup
As seen in figure 2, the setup of the perfusion system consisted of the following components:
1. Tissue bioreactor, encased in an adapted Falcon tube for sterility
2. Medium bottle
3. Peristaltic pump
4. Silicone tubing
Silicone tubing (06424, Masterflex, Cole-Parmer, USA) was chosen for its capability to allow
diffusion of gases into the medium. For the part of the tubing that is impacted by the pump, a
stronger type of tubing was used to prevent it from ripping (06508, Masterflex, Cole-Parmer, USA).
The single pieces of tubing were connected with Luer locks (11544, Qosina, USA). The open end
of the tubing, designed to later fit the bioreactor, were covered in aluminum foil and taped down to
avoid contaminations during handling. A spinner flask served as the medium reservoir, as it featured
tightly sealing entry and exit points for the tubing. Additionally, a central opening allowed easy
filling and exchanging of the medium. The chosen materials allowed to be cleaned and autoclaved in
between uses. The Luer locks were only used once, as they become brittle.
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2.3.1

Applying Sigmacote to glass capillaries
Glass capillaries (1B100-3, World Precision Instruments, USA) were submerged in Sigmacote
(SL2-100ML, Sigma Aldrich, USA) for 1 minute and left to dry. After rinsing the capillaries in
deionized water, they were heated to 100◦ C for 30 minutes. Subsequently, the capillaries were
autoclaved.

2.3.2

Flow types and flow rates
In order to actively perfuse the gel in the bioreactor, a pump supplied the medium from the reservoir
to the bioreactor. First, a peristaltic pump (Masterflex L/S, Cole/Parmer, USA) was selected to
perfuse the hydrogel construct. As this type of pump delivers pulsatile flow, the flow profile should
replicate the in vivo conditions found in an adult venous system. However, in order to achieve a more
predictable and laminar flow pattern, a syringe pump (AL300-220, World Precision Instruments,
USA) was chosen for experiments with shear rates of 4 dyn/cm2 .
As syringe pumps perfuse and retract the medium, a 2-way flow is felt by cells, which may not
physiologically represent in vivo conditions. Using the syringe pump, additionally, a cyclic perfusion
pattern was tested, where cells are subjected to 1 dyn/cm2 and 4 dyn/cm2 alternating every 4 hours.
The flow rates of the peristaltic pump were obtained by weighing the pumped volume after 10
minutes.
Finite element simulations were performed with the fluid simulation add-on of SolidWorks in order
to predict the wall shear stress, to which the cells lining the central macrochannel will be exposed to.
Shear stresses were calculated up to 3 ml/min with the following parameters:
•
•
•
•
•
•
•
•

The central channel within the gel was set as the computational domain,
Boundary condition at the outlet: 1 atm, 37◦ C,
Wall temperature was set to a constant 37◦ C,
The level of initial mesh was set to 7,
Surface roughness of the channel was approximated to 0 µm,
Water was used to approximate the properties of the medium,
A laminar and fully developed flow was chosen,
The simulation was run in respect to gravity.

2.3.3

Hydrogel stiffness
The stiffness of 5% gelatin disks were analyzed to see whether the size of the hydrogel construct had
an impact on the material stiffness. Small disks with a diameter of 2 mm and a height of 5 mm were
compared to larger disks with a diameter of 5 mm and a height of 10 mm. For this, cell-free gelatin
hydrogels were prepared following protocol 6.3.1. Disk shapes were obtained by crosslinking the
hydrogel in custom-built Teflon molds with these exact dimensions. After 1 hour of crosslinking
at 37◦ C, the disks were left to soak in medium for 30 minutes. The disks were then loaded into a
dynamic mechanical analyzer (DMA) (Q800 DMA, TA Instruments, USA) and the stiffness of the
samples was measured.

2.3.4

Cell culture
Human endothelial colony forming cells (ECFCs) were expanded in endothelial growth medium-2
(EGM-2, Lonza, Switzerland). The flasks were pre-coated with collagen I from rat tails for 30
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Table 1: Cell culture media used in the experiments

Abbreviation

Full name

Components
α-MEM (22561, Gibco, containing 2 mM L-glutamine)

EM

MSC expansion
medium

ODM

Osteogenic
differentiation
medium

10% heat-inactivated fetal bovine serum (HI-FBS, Lonza)
100 U/ml penicillin with 10 mg/ml streptomycin (15140, Gibco)
0.2 mM L-ascorbic acid-2-phosphate (ASAP, A8960, Sigma)
1 ng/ml basic fibroblast growth factor (bFGF, 233-FB R&D Systems
EM (without bFGF)

ODM (2x)

Osteogenic
differentiation
medium
(2x concentrated)

EGM-2

Endothelial growth
medium-2

EGM/ODM

Mixture of ODM (2x)
and EGM-2

10 mM β -glycerophosphate (G9891, Sigma)
10 nM dexamethasone (D8893, Sigma)
EM (without bFGF)
20 mM β -glycerophosphate (G9891, Sigma)
20 nM dexamethasone (D8893, Sigma)
Endothelial growth basal medium-2 (EBM, CC-3156, Lonza)
10% HI-FBS
100 U/ml penicillin with 10 mg/ml streptomycin
EGM-2 singlequots (CC-4176, Lonza)
1:1 mixture of ODM (2x) and EGM-2

minutes at 37◦ C before being washed three times with PBS. MSCs were expanded in MSC expansion
medium with 1% bFGF. MSCs were used at passage 4 for seeding, whereas ECFCs were used
between passages 9-11. Cells were incubated at 37◦ C and 5% CO2 with full medium changes every
3-4 days.
2.3.5

Seeding the device
Gelatin hydrogels were formed by enzymatic crosslinking with microbial transglutaminase (mTG)
(see protocol 6.3.1). In short, 10% gelatin (MedellaPro, Gelita, Germany) and 15% mTG (Activa TI,
Ajinomoto, USA) were separately dissolved in Tris-buffered saline (TBS) at 50◦ C for 15 minutes.
Meanwhile, the tissue devices were sterilized by submerging them in 70% ethanol for 10 minutes
and left to dry. Then, the bioreactor devices were washed in PBS and left to dry in a petri dish. Cells
are trypsinized and counted following protocol 6.2.2.
MSCs were used at a concentration of 5x106 per mL, whereas ECFCs were used at a concentration
of 1.25x106 cells per mL.
One bioreactor was mounted on each side of a pre-treated glass capillary (see figure 3A. It is critical
that the other side of the capillary is supported, to ensure the hydrogel gelates at an even angle. The
construct was placed next to a wet tissue within a petri dish to avoid desiccation of the hydrogel in
the incubator.
The gelatin, cells and mTG were mixed according to protocol 6.3.1 and 100 µL of the mixture
was dispensed into each tissue device. The petri dish was then incubated at 37◦ C for 1 hour. It is
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important that the in- and outlets of the bioreactor are not in contact with the wet tissue, as this may
cause draining of the hydrogel into the tissue via capillary forces and results in a half-filled device.
Furthermore, petri dishes must be sealed with parafilm, otherwise water evaporates at a fast rate and
the gelation process is impaired. Subsequently, the casted devices were incubated at 37◦ C for 1 hour.
After 1h, the capillary is carefully removed. Special care was taken to prevent detachment of the
hydrogel from the walls of the 3D-printed bioreactor. ECFCs were seeded into the generated channel
at a concentration of 12.5 x106 cells per mL (see figure 3B). For each channel, 15 µL of cell
suspension was used, resulting in 1.875x105 ECFCs per channel. The hydrogel-laden devices were
incubated for 1 hour, while turning them by 90◦ every 15-30 minutes, so that the cells can adhere to
every side of the channel.
After incubation, the channel was flushed with EGM-2 and then submerged in EGM-ODM 2x in a
12-well plate for 1 hour at 37◦ C to equilibrate the hydrogel and further promote cellular attachment
to the wall.
Meanwhile, the autoclaved perfusion setup is prepared. First, the medium reservoir was filled with
15 mL EGM-ODM 2x and the tubing on both sides was primed with liquid. After incubation, the
bioreactor was connected to the setup (see figure 3C). After connecting each side, unobstructed flow
through the lumen was ensured. Finally, the tissue device was enclosed within an adapted Falcon
tube to ensure sterility during the culture period. Before moving the bioreactor to the incubator it is
critical to clamp the tubing on each side of the Falcon tube. Otherwise, high levels of hydrostatic
pressure may be exerted onto the hydrogel by holding the bioreactor above or below the medium
reservoir.
The whole setup, including the pump, the medium reservoir, tubing and the connected tissue device
were then moved into the incubator. The medium reservoirs were placed in 3D-printed holders, as
they were prone to falling over. Furthermore, it is important to unscrew the top lid of the reservoir to
allow equilibration of air pressure. The Falcon tubes are then placed in custom-built holders that
ensure that the bioreactor are held slightly above the filing level of the reservoir in order not to cause
back pressure. When all the pieces were correctly placed within the setup, the clamps were removed
and perfusion was started.
Medium was completely exchanged every 3-4 days under sterile conditions.

2.4
2.4.1

Analyses
Immunohistological stainings
CD31/α-SMA/DAPI staining

CD31, a marker for endothelial cells, was used to visualize prevascular structures within the hydrogel
and the macrochannel throughout the gel.
After the cell culture, bioreactors were fixed in 4% formaldehyde, rinsed in PBS and permeabilised
with 0.2% Triton-X for 15 minutes. Then, the samples were blocked in PBS/BSA for 15 minutes
and rinsed in in PBS-T, then PBS.
The primary CD31 antibody was applied (mouse anti-human, Dako, M0823), diluted 1:40 in
PBS/BSA for at least 3 hours at RT or overnight at 4◦ C.
After rinsing 3 times 5 minutes in PBS-T, the secondary CD31 antibody (GE Healthcare, RPN1001v1)
was applied, diluted 1:200 in PBS/BSA, for 3 hours at RT or overnight at 4◦ C.
After rinsing 3 times 5 minutes in PBS-T, the tertiary CD31 antibody (Streptavidin Alexa fluor 488)
and the pre-conjugated α-SMA antibody (Clone 1A4, Cy3, C6198, Sigma Aldrich) are both applied
for at least 3 hours at RT or overnight at 4◦ C.

2.4 Analyses
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Figure 3: Key steps in casting, seeding and mounting the bioreactor device to a pumpA: Two
bioreactor devices were mounted on each side of the glass capillary and casted with a cell-laden
hydrogel. B: After removal of the glass capillary, the central channel was seeded with 1.875x105
ECFCs. C: After seeding, the in- and outlet of the bioreactor was connected to the pump tubing
circuit.

Then, samples were washed in PBS and incubated in DAPI, diluted 1:100, for 15 minutes. After
rinsing 3 times in PBS, the samples were imaged with a fluorescent microscope (BX51 Olympus) or
confocal microscope (TCS SP8, Leica).
Phalloidin/DAPI

Phalloidin was used to visualize the morphology of the cells within the constructs.
After the cell culture, bioreactors were fixed in 4% formaldehyde, rinsed in PBS and permeabilised
with 0.2% Triton-X for 15 minutes.
After rinsing 3 times 5 minutes in PBS, the samples were incubated in TRITC-Phalloidin, diluted
1:200 in PBS, for 1 hour at RT or overnight at 4◦ C, covered in aluminum foil.
After rinsing 3 times 5 minutes in PBS, the samples were incubated in DAPI, diluted 1:100 in PBS,
for 15 minutes at RT. After rinsing 3 times in PBS, the samples were imaged with a fluorescent
microscope (BX51 Olympus) or confocal microscope (TCS SP8, Leica).
VE-Cadherin/von Willebrand factor/DAPI

VE-Cadherin and von Willebrand factor were used as characteristic markers for ECFCs.
After the cell culture, bioreactors were fixed in 4% formaldehyde, rinsed in PBS and permeabilised
with 0.2% Triton-X for 15 minutes. Then, the samples were blocked in PBS/BSA for 15 minutes
and rinsed in in PBS-T, then PBS.
The primary VE-Cadherin antibody (rabbit anti-human, cell signaling technology, D87F2), diluted
1:250 in PBS/BSA, and the primary von Willebrand antibody, diluted 1:250 in PBS/BSA (mouse
anti-human, Abcam, 3E2D10 ab194405) were applied for at least 4 hours at RT or overnight at 4◦ C.
After rinsing 3 times 5 minutes in PBS-T, the secondary VE-Cadherin antibody (Hilyte fluor 488,
anti-rabbit IgG), diluted 1:500 in PBS/BSA, and the secondary von Willebrand antibody, diluted
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1:1000 in PBS/BSA, were applied for 4 hours at RT or overnight at 4◦ C.
Then, samples were washed in PBS and incubated in DAPI, diluted 1:100, for 15 minutes. After
rinsing 3 times in PBS, the samples were imaged with a fluorescent microscope (BX51 Olympus) or
confocal microscope (TCS SP8, Leica).
2.4.2

Live/Dead staining
Live/dead staining allows the depiction of live (green) and dead (red) cells under fluorescent
microscopy.
Prior to fixing the samples in formalin they were incubated in a mixture of calcein (1 µg/mL) and
ethidium homodimer (1 µg/mL) in PBS for 15 minutes in aluminum foil. Subsequently, the samples
were washed three times in PBS and imaged with a fluorescent microscope (BX51 Olympus).

2.4.3

Alkaline phosphatase
Alkaline Phosphatase (ALP) activity is an indicator for early bone formation.
After the cell culture, bioreactors were fixed in 4% formaldehyde, rinsed in TBS for 5 min, permeabilised with 0.2% Triton-X for 15 minutes and rinsed in TBS for 5 minutes.
Using the ALP kit (K0624, Dako, USA), 2 drops (120 µL) (120 µL) of chromogen were mixed
with 2 drops (120 µL) of the activating agent in the chemical cabinet. After 1 minute, 1.76 mL of
substrate buffer was added.
50 µL of the solution was added to each sample and samples were left to incubate for 30 – 60
minutes at RT in aluminium foil. When the red stain was intense throughout the construct, the
reaction was terminated by washing the sample in deionized water until the red dye was removed.
Samples were then analysed with a stereoscopic microscope (SZ61, Olympus, Japan).

3. Results & Discussion

First, a non-cytotoxic material was chosen for the bioreactor to be 3D-printed in. Then, a computational model was generated to relate flow rates to a wall shear stress during perfusion. Furthermore,
gel stiffness was analyzed. Once a suitable gel stiffness was identified, the biological evaluation of
the platform was initiated, where cell-laden gels were perfused and subsequently analyzed.

3.1
3.1.1

Assessing properties of bioreactor platform
Assessing 3D-printed materials on their cytotoxicity
Even after (repeated) post-treatment of the 3D-printed structure, cytotoxic photo-crosslinker residues
may still leach out. Therefore, a viability test with Alamar Blue was performed on MSCs.
As can be seen in figure 4, Alamar Blue showed full viability of MSCs when supplied with medium
pre-conditioned with Pic100 and E-Shell (clear) polymer, compared to MSCs which received
untreated medium. R05 showed a similar viability, whereas E-Shell (beige) and PR48 showed lower
cell survival. While flashing PR48 constructs with a higher amount of light cycles to further enhance
the hardening of uncured resin (2500 and 4000 cycles) resulted in a 12% higher viability, it did not
prove to be enough to minimize cytotoxicity.
Pic100 resin was chosen for printing the bioreactor due to its high cyto-compatibility and very
high printing resolution of 25 µm.
R05 was rejected due to its printing resolution of 50 µm, and E-Shell (clear) was rejected as it can
only be printed in the Autodesk Ember printer, causing regular failure of the printed splinter due to
its sideway moving motion between printed layers. E-shell beige and PR48 were both rejected due
to their high toxicity on MSCs.
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Figure 4: Influence of 3D-printed materials for SLA printing on metabolic activity of MSCs.
Preconditioned medium with chips of the commercially available materials PIC100, R05 and E-shell
(clear) show highest compatibility with MSC cultures when compared to MSC performance in not
treated medium (set to 100%) (N=3).
3.1.2 Flow speed of pump and impact on shear stress
Wall shear stress is defined as the force that a viscous fluid exerts onto the inner surface of a vessel
per unit area [20].
The flow speeds of the pump were measured and then used to calculate the wall shear stress in the
channel using a computational model. A linear coherence was calculated to be Y = 2.56 * X – 0.05,
where X is the flow rate in mL/min and Y is the shear stress in dyn/cm2 , giving an easy way to relate
the two parameters. The depicted correlation is only applicable to this channeled construct with a
diameter of 1 cm and follows the assumptions made earlier.

Figure 5: Correlation of flow rate to shear stress within the macrovessel (Ø = 1 cm)
Flow rate (X) and shear stress (Y) show a linear correlation following Y = 2.57 * X – 0.05

3.2 Biological evaluation of shear rates

3.1.3
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Hydrogel properties
Dynamic mechanical analysis showed that large constructs were softer than smaller constructs with
the same gelatin concentration (figure 6A). Large constructs with a volume of 785.3 mm3 showed an
average elastic modulus of 5.22 kPa, whereas smaller constructs with a volume of 62.8 mm3 showed
an elastic modulus of 7.43 kPa.
The ability of ECFCs to from a vascular system is dependent on the stiffness of the surrounding
matrix [21]. Previous work of the group showed sprouting of ECFCs within 3.5% gelatin hydrogel
disks[22], resembling the small disks used for DMA. As can be seen in figure 6B, C, and D , a higher
gelatin concentration allowed to better retain the shape of the channel after removal of the splinter.
Given the measured difference in stiffness, bioreactors may be casted with a higher gelatine concentration to ensure shape fidelity of the channel, while still providing a matrix stiffness allowing the
spreading of ECFCs.

Figure 6: Large gelatin disks are softer compared to smaller disks with the same gelatin
concentration B, C, D: A higher gelatin concentration allowed a higher shape fidelity of the channel
(N=3)

3.2 Biological evaluation of shear rates
3.2.1 Peristaltic flow, 7 days, 0.7 dyn/cm2
Co-cultures of MSCs and GFP-labeled ECFCs were encapsulated in 5% Gelatin hydrogels within
the tissue chamber in the bioreactor device and the channel was lined with GFP-labeled ECFCs.
A peristaltic pump supplied medium at a flow rate of 0.26 mL/min, causing a shear stress of 0.7
dyn/cm2 .
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As seen in figure 7, the channel was still lined with ECFCs, showing nearly confluent coverage
and cobblestone morphology after a culture period of 7 days.
In the bulk hydrogel, stretched EFCFs were visible in the outer corners of the construct but not
surrounding the channel. Furthermore, ALP staining was most pronounced at the outer parts of the
hydrogel. Interestingly, a ring-shaped area clearly distinguished ALP-negative and -positive parts
surrounding the channel. ALP activity collocated with the stimulation of ECFCs in the corner, seen
in figure 8B.
Phalloidin/DAPI staining showed that cells were prevalent and alive throughout the whole construct,
independent of the ring shape.
Moreover, perfused constructs showed α-SMA throughout the construct, as opposed to static
controls.
A possible explanation for the ring shaped area around the channel could be the pulsatile nature
of peristaltic flow. During the perfusion, gels were seen to inflate several millimeters when medium
pulsed through the channel and subsequently swing back to their original size when medium seized
to flow. High pulsatile forces may have compressed the hydrogel around the macrovessel, repressing
metabolic activity of ECFCs surrounding the channel, resulting in a lower expression of GFP.
Moreover, a higher GFP-signal was seen on the top, where the gel could freely swing without
compression.
Collocation of strong ALP signal and stretching ECFCs in the corners indicated the ability of the
co-culture to stimulate itself towards osteogenic differentiation. While GFP and ALP activity within
the ring may suggest that cells died or migrated away from the channel, Phalloidin/DAPI showed the
presence of cells throughout the whole construct.
The presence of α-SMA may indicate that MSCs differentiated into perivascular cells. In this
experiment, stabilizing (α-SMA+ ) structures were formed throughout the gel, however ECFCS were
only able to stretch in the corners, not resulting in a microvascular bed throughout the construct.

Figure 7: Channeled construct was still lined with ECFCs after perfusion of 7 days at 0.7
dyn/cm2
(right) cross-section showed cobblestone morphology and monolayer of GFP-labeled ECFCs in
channel. (left) surface of channel at 63x magnification.

3.2 Biological evaluation of shear rates
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Figure 8: Channelled constructs perfused at 0.7 dyn/cm2 for 7 days compared to a static
control.
A, E: GFP-ECFC stretched in the corners, whereas a lower activity was seen around the channel.
B, F: Higher osteogenic differentiation was seen outside of ring. C, G: Phalloidin indicated cell
presence throughout the construct D, H: MSCs differentiated into α-SMA+ -stabilizing cells when
subjected to flow
3.2.2

Peristaltic and laminar flow, 5 days, 1-4 dyn/cm2
Lined co-cultures of MSCs and ECFCs were subjected to a shear stress of 4 dyn/cm2 from a peristaltic pump and a cycling shear from a syringe-pump for 5 days. The syringe-pump switched
between 1 dyn/cm2 and 4 dyn/cm2 every 4 hours.
3.5% gelatin constructs showed no lining of endothelial cells after 5 days of peristaltic perfusion,
compared to a static control. Figure 9A shows an undefined transition between the gel and the
channel, whereas the static culture (fig. 9C) showed VE-Cadherin-expressing ECFCs on the outline
of the channel.
4% gelatin constructs, perfused by a cycling syringe-pump, allowed proper cellular attachment
comparable to the static control. In figure 9B, a clear transition between the channel and the gel can
be seen by VE-Cadherin-expressing ECFCs that is comparable to the static control (fig. 9D). In both,
the perfused and the static samples, von Willebrand factor was visible.
Perfusion with a syringe-pump showed a higher cell survival compared to the peristaltic pump (figure
10A, C). Furthermore, no Phalloidin was seen in the area directly adjacent to the perfused channel in
both types of perfusion. (figure 10B, D)
To summarize, a pulsatile shear rate of 4 dyn/cm2 caused abrasion of the channel surface, whereas
cycling laminar perfusion at the same shear rate allowed attachment and proliferation of ECFCs.
Presence of VE-Cadherin on the channel surface is crucial for permeability of the endothelial layer
and for cell-to-cell adhesion [23].
Price et al. have reported, that vascular stability is affected by perfusion stress [24]. Using channels
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Figure 9: Comparison of peristaltic perfusion and perfusion with a syringe-pump.
A, C: Peristaltic perfused channel showed abrasion of endothelial layer and hydrogel B, D: Syringeperfused channel showed VE-Cadherin-expressing ECFCs lining the channel

lined with ECs in gelatin, the group showed that a high flow rate, and therefore a high transmural
pressure, eliminated leaks by stabilizing the vessel. Moreover, they reported that high shear stresses
(>10-15 dyn/cm2 ) would eliminate leaks by maintaining a positive transmural pressure [25].
3.2.3

Peristaltic vs laminar flow, 7 days, 4 dyn/cm2
Lined co-cultures of MSCs and ECFCs were subjected to a continuous shear stress of 4 dyn/cm2
from a syringe-pump for 7 days. Endothelial cells showed a similar morphology within the gel and
on the channel surface compared to the static control. After 7 days, no capillary-like network was
visible and no sprouting from the central channel was seen. However, in both conditions, endothelial
cells expressed CD31 (figure 11). Additionally, α-SMA expression was seen on the surface of the
channel and within the gel. ECFCs were not seen to stain double-positive for αSMA and CD31.
When compared to co-cultures that were subjected to pulsatile perfusion at 1 dyn/cm2 (figure 8), the

3.2 Biological evaluation of shear rates
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Figure 10: Comparing the impact of peristaltic perfusion and perfusion with a syringe-pump
on cellular survival and morphology.
A, C: Perfusion with a syringe-pump showed higher cell survival B, D: In both types of pump, less
Phalloidin was seen in the area adjacent to the channel.
constructs showed a similar distribution of endothelial cells, and a similar expression of α-SMA.
ALP staining showed no osteogenic differentiation of MSCs in the continuously perfused construct
and its static control after 7 days (figure 12).

The presence of α-SMA suggested that MSCs differentiated towards perivascular cells, ready to
stabilize potential vascular networks, however no networks were formed in any of the experiments.
In previous work done by the group, sprouting of ECFCs, co-cultured with MSCs, was seen to
occur within mTG-hydrogels cultured for 10 days [22]. In our research, it remained unclear whether
ECFCs would have been able to sprout, when subjected to longer cultivation or if the conditions
within the bulk hydrogel were insufficient to support the formation of a vasculature. Culture periods
were limited to five or seven days, as hydrogels ruptured either due to perfusion conditions or
handling mistakes. In general, data about shear-induced sprouting of ECs and its time points diverges
greatly in the literature [16] [26]. While Galie et al. reported that sprouting only occurs at shear rates
greater than 10 dyn/cm2 , accounting elevated levels of matrix metalloproteinase 1 for this effect 5,
the majority agreed that high shear stresses cause a growth arrest in ECs. For example, HUVECs
reportedly only sprouted in nearly static conditions at shear stresses lower than 1 dyn/cm2 at day 3-4
[16]. Other groups, however, have shown that bovine aortic ECS sprouted at 3 dyn/cm2 , but not at
1.5 dyn/cm2 and that activation of p53 triggered a signaling cascade that inhibited further EC growth
[27].
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Figure 11: Tissue constructs (4% gelatin), perfused for 7 days with a syringe-pump at 4
dyn/cm2 , have a similar expression of CD31 compared to a static control

Figure 12: 4% gelatin construct perfused at 4 dyn/cm2 for 7 days using a syringe pump
showed no expression of ALP, similar to its static control

4. Conclusion & Future Outlook

In this study we have developed a culture chamber with a perfusable central channel throughout
a hydrogel and assessed the effect of pulsatile and laminar flow on cell survival, channel lining,
channel sprouting and osteogenic differentiation.
The developed bioreactor platform was capable of perfusing a channeled construct with high cell
survival throughout the hydrogel.
Laminar flow, compared to pulsatile flow, proved to be the more suitable type of flow, as gels did not
get inflated and strained, exerting uncontrollable forces onto the cells. Additionally, even at higher
shear rates of 4 dyn/cm2 , laminar flow did not cause abrasion of the lined channel, allowing the
attachment of ECFCs and subsequently the formation of a macrovessel.
Throughout the whole construct, MSCs appeared to have differentiated into smooth muscle cells,
serving as mural cells for stabilizing a potential vascular networks. However, a vascular bed did not
develop in any of the experiments.
A limitation of this study is the lack of systematic characterization of flow rates. So far, only the first
steps in assessing the platform’s perfusion limits were taken. Further research will show whether
longer culture periods and cyclic perfusion patterns may aid in vascular sprouting and will show
their impact on osteogenic differentiation.

5. Supplementary
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Figure 13: Interactive 3D Render of the uncasted bioreactor model

Table 2: Ovrview of bioreactor experiments
Cell donors
1
2

MSC 59 (P4)
GFP-ECFC 17 (P11)
MSC 59 (P4)
GFP-ECFC 17 (P11)

Gelatin
conc.

Type of
perfusion

Shear rate

Duration

Analyses

5%

peristaltic

1 dyn/cm2

7d

GFP/α-SMA/DAPI,
ALP, Phalloidin

5%

perisaltic

1 dyn/cm2

10d

GFP/DAPI

3

MSC 57 (P4)
ECFC 17 (P11)

3.5%

peristaltic

4 dyn/cm2

5d

live/dead, Phalloididn/DAPI,
VE-Cadherin/
von Willebrand factor/ DAPI

4

MSC 57 (P4)
ECFC17 (P11)

4%

peristaltic

4 dyn/cm2

5d

live/dead, Phalloidin

5

MSC 57 (P4)
ECFC 17 (P11)

4%

syringe-pump,
cyclic

1-4 dyn/cm2
cycling every 4h

5d

6

MSC 57 (P4)
ECFC 17 (P11)

4%

syringe-pump,
non-cyclic

4 dyn/cm2

7d

live/dead, Phalloidin, ALP,
VE-Cadherin/von Willebrand factor/
DAPI
live/dead, ALP,
CD31/α-SMA/DAPI

Remarks

infected,
results not shown

static control of
Phalloidin taken
from experiment 5

6. Protocols

6.1

Cell culture media
These protocols are based on the protocols from Kaak drive and Yee Xiang Chang.
The FBS used during this study was FBS HI biowest (lot: S14068S1810).

6.1.1

MSC expansion medium
Table 3: MSC expansion medium
For 50 mL
44 mL
5 mL
500 µL
500 µL
50 µL

6.1.2

Component
α-MEM (22561 Gibco, 2 mM I-glut)
heat-inactivated Fetal Bovine Serum
L-ascorbic acid-2-phosphate (A8960 Sigma)
PenStrep (15140 Invitrogen)
bFGF

Stock concentration
20 mM
1 µg/mL

Final concentration
10 %
0.2 mM
1%
1 ng/mL

MSC osteogenic differentiation medium
Table 4: MSC osteogenic differentiation medium
For 50 mL
44 mL
5 mL
500 µL
500 µL
500 µL
0.2 µL

Component
α-MEM (22561 Gibco, 2 mM I-glut)
heat-inactivated Fetal Bovine Serum
L-ascorbic acid-2-phosphate (A8960 Sigma)
PenStrep (15140 Invitrogen)
β -glycerophosphate (G9891, Sigma)
Dexamethasone (D8893 Sigma)

Stock concentration
20 mM
1M in PBS
1 mg/mL

Final concentration
10 %
0.2 mM
1%
10 mM
10 nM
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6.1.3

Endothelial Growth Medium -2
Table 5: Endothelial Growth Medium -2
For 560.2 mL
500 mL
50 mL
5 mL
0.5 mL
0.5 mL
0.5 mL
0.5 mL
0.5 mL
0.5 mL
2.0 mL
0.2 mL

Component
EBM-2 (CC-3156, Lonza)
heat-inactivated Fetal Bovine Serum
PenStrep (15140 Invitrogen)
Heparin (CC-4396A)
R3 -IGF-1 (CC-4115A)
rhEGF (CC-4317A)
GA-1000 (CC4381A)
Ascorbic Acid (CC4116A)
VEGF (CC-4114A)
rhFGF-B (CC-4113A)
Hydrocortisone
*

6.2

Cell culture

6.2.1

Thawing cells

Final concentration
8,9 %
0,89%
*
*
*
*
*
*
*
*

EGM-2 SingleQuots (CC-4176, Lonza)

Materials:
• Water bath at 37◦ C
• Medium
• Cryotube containing frozen cells
• Pipettes
• Cell counter (incl. cell counting slides) (Bio-Rad TC-20; 145-0011)
• Trypan Blue solution (Sigma T8154)
• Cell culture flasks
Procedure:
• Prepare 7 mL of medium in Falcon tube
• Thaw Cryotube in water batch (37◦ C)
• Transfer content into prepared Falcon tube
• Spin down immediately to separate cells from DMSO
• Aspirate supernatant and dissolve pellet in 1-2 mL of fresh medium
• Count cells:
– Mix 10 µL of cell suspension with 10 µL of Trypan Blue solution
– Transfer 10 µL of solution into cell counting chamber and insert into cell counter
Depending on the required cell density, cells are cultured in differently sized flasks.
For this study, MSCs were cultured in T175 flasks at a starting density of 0.3x106 cells/mL, whereas
ECFCs were cultured in T75 flasks with a starting density of 0.1x106 cells/mL.

6.2 Cell culture
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• Prefill culture flask with culture medium (T175: 25 mL, T75: 12 mL)
• Add required starting density of cells into prefilled culture flasks
• MSCs require 0.1 % bFGF added to the flask with every medium change
6.2.2

Trypsinizing cells
Materials:
• Pipettes
• Trypsin
• Confluent cell culture flask
• PBS
• Cell culture medium
Procedure:
• Remove old medium
• Wash cells with 10 mL of PBS
• Add 1 mL of Trypsin to T75 or 2 mL to T175 flasks
• Incubate at 37◦ C for max. 5 minutes
• Gently tap the sides to detach cells from flask
• Dilute with 4x the amount of Trypsin to stop the reaction
• Wash culturing surface with fresh medium and aspirate the solution
• Dispense the solution into 50 mL Falcon tube and spin it down
• Discard supernatant and dissolve pellet in 1-2 mL of fresh medium
• Count cells:
– Mix 10 µL of cell suspension with 10 µL of Trypan Blue solution
– Transfer 10 µL of solution into cell counting chamber and insert into cell counter
Depending on the further intent, cells were either re-seeded culture flask or prepared into a stock
solution for seeding. To prepare a stock solution, the cells are centrifuged and re-dissolved in a
different volume, following this formula: c1 ∗V1 = c2 ∗V2

6.2.3

Freezing cells
Materials:
• Mr. Frosty at RT
• Cell freezing medium A
– 40% FBS in α-MEM
• Cell freezing medium B
– 20% DMSO in α-MEM, then sterile filtered
• DMSO (Uvasol, Merck, Germany)
• Cryotubes
Procedure:
• Place Mr. Frosty at room temperature
• Count cells (see Protocol 6.2.2)
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•
•
•
•
•

6.3
6.3.1

Resuspend cells in cell freezing medium A (0.5 mL/Mio cells)
Fill each cryotube with 0.5 mL of the cell suspension
Slowly add 0.5 mL of cell freezing medium B
Resuspend once
Place vials in Mr. Frosty and freeze at -80◦ C

Preparation of hydrogels
Enzymatically cross-linked gelatin hydrogel (mTG) with cells
Materials:
• Gelatin (MedellaPro, Gelita, Germany)
• mTG (Activa TI, Ajinomoto, USA)
• Block heater (VWR, Thermal shaker touch)
• TBS
• MSC/ECFCs
• Eppendorf tubes
• Syringes
• Syringe filters (0.22 µm pore diameter)
Procedure:
• For a 10% gelatin solution, add 1000 µL of TBS to 100 mg of gelatin.
• For a 15% mTG solution, add 1000 µL PBS to 150 mg of mTG.
• Heat both Eppis up to 50◦ C for 15 minutes
• Sterilize the mTG-solution by filter sterilization
• Before use, pre-heat both solutions to 37◦ C
The gel is composed of 10% of each cell type and the previously mixed ingredients in their respective
percentages. If required, the solution can be diluted with PBS.
For 100 µL of a 5% Gelatin and 4,5% mTG solution, the following ingredients were mixed:
• 10% Gelatin: 50 µL
• MSC: 10 µL
• ECFCs: 10 µL
• 15% mTG: 30 µL
In this case, no additional TBS is required.
After adding the mTG, the solution solidifies, so immediate dispensing is required!

6.3.2

Hydrogel disks with superficial ECFC seeding

Materials:
• Gelatin solution in PBS (see procedure 6.3.1)
• Sterile mTG solution in desired concentration (see procedure 6.3.1)

6.4 Setup of perfusion bioreactor
•
•
•
•
•
•
•
•
•
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EGM-2 medium
PBS (sterile)
ECFC cells
Trypsin
Silicone moulds (8 mm in ø, 1 mm in height)
70% Ethanol
50 ml Falcon tubes
6-well plate
Tweezers

Procedure:
• Required Gelatin solution may be dissolved on the preceding day
• Sterilize the tweezers and silicone moulds in Ethanol and let dry
• Wash the dry silicone moulds in PBS and let dry
• Use the tweezers to place the silicone moulds in a 6-well plate and press them to the base
• Prepare the desired concentration of gelatin hydrogel (see procedure 6.3.1)
• 60 µL are required per silicone disk
• Let cross-link at 37◦ C for 1 hour
• Trypsinize cells according to protocol 6.2.2
• Prepare a stock solution with a concentration of 12.5x10 6 / mL medium ( see protocol 6.2.2)
• Dispense stock solution onto cross-linked disks until the surface is fully covered.
• Incubate at 37◦ C for 1 hour
• Fill well with EGM-2 medium until the disks are fully immersed
• Incubate at 37◦ C for 10 days and change the medium every 3-4 days

6.4

Setup of perfusion bioreactor

6.4.1

Build and autoclave the circuit

Materials:
• Masterflex clear tubing (06424, Masterflex, Cole-Parmer, USA)
• Masterflex pump tubing (06508, Masterflex, Cole-Parmer, USA)
• Spinner flask
• Luer locks (male/female) (11544, Qosina, USA)
• Falcon tube (50 mL)
• Drill press
• Alu-foil and tape
• Soap
• 70% Ethanol
• Autoclave bag
• Autoclave
Procedure:
• Cut 4 pieces of Masterflex clear tubing, 15 cm
• Cut 2 pieces of Masterflex pumping tubing 15 cm
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•
•
•
•
•
•
•
•
•
6.4.2

Insert clear tubing through holes in spinner flask inlet
Use male/female Luer locks to interconnect the tubing as shown in figure 2
Use a drill press to drill a hole into the lid and the conical end of a 50 mL Falcon tube
Arrange the Falcon tube as seen in figure 2
Wash the whole circuit with soap water, then flush it with 70% ethanol
Blow the circuit dry with compressed air
Cover the endings of the tubing with Alu-foil and tape to avoid contamination upon sterilization
Clean the inside of spinner flask with soap water
Place into autoclave bag and autoclave at 121◦ C.

Treat and autoclave glass capillaries
Materials:
• Glass capillaries (1B100-3, World Precision Instruments, USA)
• Sigmacote (SL2-100ML, Sigma Aldrich, USA)
• Deionized Water
• Empty pipette tip box
• Tissues
• Autoclave
Procedure:
• Glass capillaries are submerged in Sigmacote solution (within bottle)
• The reaction is almost instantaneous
• Capillaries are removed from solution and left to air dry in a fumehood
• The siliconized capillaries are then washed in deionized water for 1 minute and left to dry.
• An empty pipette tip box is filled with tissues to the top
• The dry capillaries are then placed on top of the tissues
• The box is closed and autoclaved

6.4.3

Encapsulation of MSCs and ECFCs in a channeled hydrogel
Materials:
• Gelatin solution in PBS (see procedure 6.3.1)
• Sterile mTG solution in desired concentration (see procedure 6.3.1)
• Bioreactors
• Glass capillaries (in autoclaved box including sterile tissues)
• ECFCs
• MSCs
• Tweezers
• 70% Ethanol
• PBS
• Petri dish
• Parafilm
Procedure:

6.4 Setup of perfusion bioreactor
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1. General Preparations
• Sterilize tweezers in ethanol and let them air dry
• Place bioreactors in ethanol and let air dry
• Place bioreactor in PBS to wash away any ethanol residues and let air dry
2. Preparation of hydrogel
• Follow protocol 6.3.1
3. Preparation of bioreactor
• Insert sterile and coated glass capillary through both ends of bioreactor
• Insert 1 bioreactor on each side of the capillary to get straight channels
• Place construct in a petri dish
• Add sterilized mTG solution and immediately dispense 100 µL into the central chamber,
making sure that the connectors of the bioreactor fill up as well
• Place a sterilized tissue (from the pipette tip box 6.4.2) in the petri dish and wet it with 1
mL of sterile PBS
• Wrap the petri dish with parafilm.
Important, otherwise insufficient gelation.
• Place at 37◦ C for 1 hour
4. Casting & Seeding
• After 1 hour, carefully remove splinter by twisting the capillary around its own axis
• After detachment, the capillary can be removed by pulling and twisting simultaneously
• Trypsinize and concentrate ECFCs according to 6.2.2 to a final concentration of 12.5
Mio ECFCs per mL
• Aspirate 15 µL of cell suspension and fill central channel
• Place bioreactor in petri dish with wet tissue and seal with parafilm
• Place the sealed petri dish in the incubator.
• Every 30 minutes, remove the petri dish and turn the bioreactor by 90◦ in order for the
cells to properly attach to all sides of the channel through gravity
• Submerge the bioreactor in EGM/ODM2x medium over night
• The next day, the channel is flushed with medium to remove any unbound ECFCs
6.4.4

Connecting the bioreactor to the peristaltic pump
Materials:
• Autoclaved perfusion circuit (see protocol 6.4.1)
• EGM/ODM2X cell culture medium
• Clamps (3D-Printed)
• Falcon tube holder (3D-printed)
• Spinner flask holder (3D-printed)
• Perfusion pump (Masterflex LS Cole-Parmer)
• Tweezers
Procedure:
• Fill spinner flask with 20 mL of EGM/ODM 2x medium
• Connect one tube to the pump and fill it with medium
• Place tweezers into tubing to widen the hole
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• Attach bioreactor to one side of the tubing
• When connected, place clamp around tubing in order not to destroy the channel due to sudden
movements or backlashing liquids
• Disconnect the tubing from the pump and repeat procedure for the second tubing (including
placing the clamps)
• When both ends are connected, place Falcon tube around the bioreactor and close it up to keep
the construct from getting infected
• Repeat the above steps when multiple bioreactors are attached
• Place the pump, the medium reservoir and the connected bioreactor (with clamps) into the
incubator
• To avoid the spinner flasks from falling, place it into 3D-printed holder
• Place the Falcon tube into the 3D-printed holder and attach the holder to the above level of the
incubator
• Only when all the components are in place, remove the clamps and slowly turn the pump up
to the desired pumping speed

6.5
6.5.1

Analysis
Viability Test with Alamar Blue
Materials:
• Alamar Blue solution (B21187, Alfa Aesar, USA)
• 48-well plate
• MSCs
• MSC expansion medium
• Fluoroskan (Ascent, Thermo Fisher, USA)
• SOP 69 Research Lab Orthopedics
Procedure:
1. Calibration Curve
• Pre-incubate 30 mL of medium to account for preconditioning in main experiment for 3
days at 37◦ C, then store in fridge
• Cultivate 5 cell densities for 1 day in pre-incubated medium (n=3) densities: 5.000,
10.000, 20.000, 35.000, 50.000
• Add Alamar blue and measure fluorescence
• Create calibration curve
• Use calibration curve to determine optimal cell density for main experiment.
Optimal cell density is right before the calibration curve reaches its plateau.
2. Main experiment
• Precondition medium by soaking 3D printed parts in medium for 3 days
• Culture cells in optimal density in preconditioned medium (n = 3) for 1 day
• Culture control in untreated medium (n = 3) for 1 day
• Add Alamar Blue and measure fluorescence
3. Readout
• Fluorescence of control is 100% viability
• Fluorescence of cells in conditioned medium should be below!

6.5 Analysis
6.5.2
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Triple staining CD31/aSMA/DAPI
Materials:
• Sample: Sliced bioreactor previously fixated in 4% Formalin in PBS
• PBS
• PBS-Tween 0.1% (PBS-T)
• 5% BSA in PBS
• 0.2% Triton-X in PBS
• CD31 antibody (mouse anti-human, Dako, M0823)
• (CD31 2nd) Sheep anti-Mouse biotinylated (GE Healthcare, RPN1001v1)
• (CD31 3rd) Streptavidin Alexa fluor 488
• α-SMA antibody
• DAPI stock solution (1:100 in PBS) from -20◦ C freeze
Procedure:
• Wash sample in 96-well plate in PBS for 5 minutes
• Permeabilise with 0.2% Triton-X in PBS for 15 minutes.
• Block 15 min in PBS/BSA
• Rinse in PBS-T, then PBS.
• Incubate primary antibody CD31, 1:40 in PBS/BSA 5%, for at least 3 hours at RT or overnight
at 4◦ C.
• Rinse 3x 5min in PBS-T
• Incubate secondary antibody CD31, 1:200 in PBS/BSA 5%, for at least 3 hours at RT or
overnight at 4◦ C.
• Rinse 3x 5min in PBS-T
• Incubate α-SMA antibody, 1:300 in PBS/BSA 5%
and tertiary antibody, 1:400 in PBS/BSA 5%, for at least 3 hours at RT or overnight at 4◦ C.
• Rinse 3x in PBS
• Incubate at RT with DAPI 1:100 in PBS for 15 minutes in Alu-foil
• Rinse 3 times in PBS and leave the samples in PBS

6.5.3

Phalloidin staining
Materials:
• Sample: Sliced bioreactor previously fixated in 4% Formalin in PBS
• PBS
• 0.2% Triton-X in PBS
• TRITC-Phalloidin (red fluorescent)
• DAPI stock solution
Procedure:
• Place a slice of the bioreactor tissue in 96-well plate
• Rinse in PBS for 5 minutes
• Permeabilize in 0,2% Triton-X in PBS for 15 minutes
• Rinse in PBS 3x for 5 minutes each
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• Incubate in TRITC-Phalloidin solution 1:200 in PBS for 1 hour at RT in Alu-foil or overnight
at 4◦ C
• Rinse in PBS 3x for 5 minutes each
• Incubate at RT with DAPI 1:100 in PBS for 15 minutes
• Wash in PBS 3x 5 minutes and leave samples in PBS
6.5.4

Triple staining VE-Cadherin/von Willebrand/DAPI
Materials:
• Sample: Sliced bioreactor previously fixated in 4% Formalin in PBS
• PBS
• 0.2% Triton-X in PBS
• 5% BSA in PBS
• VE-cadherin antibody (cell signaling technology, rabbit anti-human D87F2)
• (VE-cadherin 2nd) Hilyte fluor 488 (anti-rabbit IgG)
• Von willebrand antibody (Abcam, mouse anti-human, 3E2D10 ab194405)
• (Von willebrand 2nd) Alexafluor 546 (goat anti-mouse)
• DAPI stock solution
Procedure:
• Place a slice of the bioreactor tissue in 96-well plate
• Rinse in PBS
• Permeabilize with 0.2% Triton-X in PBS for 15 minutes
• Block 15 min in PBS/BSA
• Rinse in PBS-T (5min), then PBS (5 min)
• Incubate primary antibody VE-cadherin, 1:250 in PBS/BSA 5%
and von Willebrand 1:250 for at least 4 hours at RT.
• Rinse 3x 5min in PBS-T
• Incubate secondary antibody VE-cadherin, 1:500 in PBS/BSA 5%
and secondary antibody von willebrand 1: 1000, for at least 4 hours at RT
• Rinse 3x in PBS
• Incubate at RT with DAPI for 15 minutes 1:100 in PBS in Alu-foil
• Rinse 3 times in PBS and leave the samples in PBS and wrapped in Alu-foil

6.5.5

Live/Dead (Calcein) staining
Materials:
• Calcein, AM (Invitrogen C3100MP)
• Ethidium Homodimer 2mM in DMSO
• PBS
Procedure:
• Use sample prior to fixating in formalin!
• Incubate sample in mixture of Calcein (1 µg/mL) and Ethidium Homodimer (1 µg/mL) in
PBS for 15 minutes
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• Wash 3x in PBS and keep in PBS until imaging
6.5.6

ALP assay (Dako)
Materials:
• TBS
• 0.2% Triton-X in TBS
• ALP kit Dako K0624 (Fuchsin chromogen)
• 3 drops (120 µL) of chromogen and 3 drops (120 µL) of activating agent
• Mix and wait 1 minute
• Add 1.76 ml 1.76 ml substrate buffer (2 mL in total)

Chromogen solution is toxic. Handle only under fume hood.
Procedure:
• Sample: Sliced bioreactor previously fixated in 4% Formalin in PBS
• Rinse in TBS for 5 minutes
• Rinse 2x in TBS for 5 minutes
• Permeabilise in 0.2% Triton-X in PBS for 15 minutes
• Rinse in TBS for 5 minutes
• Prepare the ALP staining solution as described above in the fume hood.
• Incubate samples in 50 µL of the ALP staining solution for 30 - 60 minutes at RT in Alu-foil
• Reaction is terminated when the red staining is intense throughout the entire construct, by
washing the sample in deionized water.
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